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1 INTRODUCTION
Natural Products (naturally occurring organic chemical compounds) from
worldwide sources such as plants, animals, marine organisms or microorganisms, have
always fascinated chemists. Interesting and intriguing chemistry is involved in their in vivo
production and in their laboratory utilization. Their role as biologically active molecules,
(substrates for life processes, toxins, hormones, drugs, etc.) and as novel structural
materials, is of unparalleled importance. Knowledge of their biological properties is
important, not only for the discovery of new therapeutic agents, but also for the extension
of basic knowledge for further drug development. In addition, chemical substances from
natural sources can be easily degraded by biological pathways where no toxic waste
remains that otherwise might cause pollution.
The search for marine natural products, the secondary or non-primary metabolites
produced by organisms that live in the sea, is a relatively new area of research. Marine, as
well as terrestrial organisms, produce this class of chemicals to provide the organism with
an advantage over its neighbors. Marine invertebrates such as sponges, corals and tunicates
are among the well-researched organisms primarily because of their size and abundance.
Another interesting fact is that the majority of bioactive marine natural products have been
isolated from soft-bodied, sessile or slow-moving marine invertebrates.1 They are devoid
of morphological defense structures, such as spines or protective shells, which
demonstrates the ecological importance of these metabolites for responding to
environmental stress. Here natural products are used to fight off potential predators, or to
force back competing neighbors.2 This form of chemical warfare has resulted in some of
nature's most toxic chemicals.
To date most of the pharmaceuticals that are derived from natural products have
been obtained from terrestrial organisms. However, the marine environment was largely
untapped and unknown as far as chemistry goes, and in recent years led to a vast array of
novel organic molecules. Many of these molecules possess unique structural features that
are enormous and specific enough to protect the organisms in a very hostile environment.
New drug discoveries indicate that marine organisms have a tremendous potential for new
pharmaceuticals and will become a much more prolific source than any other group of
terrestrial organisms. Among the marine toxins that shows promising biological activities,
the cyclodepsipeptide jasplakinolide (1) is a notable example.
2 INTRODUCTION
Jasplakinolide was isolated from the marine sponge Jaspis sp.3 This compound
shows potent antifungal, insecticidal and antitumor activity. These activities are due to the
interaction with actin filaments. Therefore, jasplakinolide is also an important biochemical
tool. It represents a new class of bioactive cyclodepsipeptides. The structure incorporates
both peptide and polypropionate units. It is part of a growing family of structurally related
marine-derived natural products; geodiamolides A-F, TA, and neosiphoniamolide (see next
chapter). Their structures differ in the composition of the tripeptide, but share the same 11-
carbon polypropionate unit.
Figure 1: Structure of jasplakinolide (1) and geodiamolide.
Jasplakinolide and other related cyclodepsipeptides possess very high activity
against a number of tumor-derived cell lines, and therefore appear to be very promising
candidates for cancer chemotherapy. This has made them very attractive for further
biological investigation and structure-activity relationship (SAR) studies. However, their
low natural abundance reflects the scarcity of these compounds. For example, only 1 mg of
jasplakinolide can be obtained from 3.3 kg of fresh marine sponge Jaspis sp.3b The current
price for this compound in research chemical amounts is about $4000 per mg.4
Accordingly, total syntheses of jasplakinolide, as well as others in this family, has become
an attractive and challenging option.
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Scheme 1: The retrosynthetic pathway to jasplakinolide (1).
Here, in this work a total synthesis of jasplakinolide and tripeptide part is not
proposed. Instead, our target was an efficient synthesis of the polypropionate unit. The
work to be presented in this project describes a new synthesis of the 8-hydroxy-nonenoic
acid (3b) from commercially available starting materials. It further includes an extensive
review for the preparation of this compound. As noted earlier, jasplakinolide is being used
as an important biochemical tool in cytoskeletal research. In addition, the synthesis of
analogs with different substituents at C2 and/or C8 using similar key steps was
investigated.
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2 LITERATURE REVIEW
2.1 Historical Account of Jasplakinolide
Jasplakinolide (jaspamide),3 was first time reported in 1986 as a novel biological
active cyclodepsipeptide. It was isolated from the Indo-Pacific marine sponge Jaspis
johnstoni (order Astrophorida; family Jaspidae).5 It is now known as Jaspis sp. or Jaspis
splendens.6 The cyclic depsipeptide was initially described as an antimicrobial,
insecticidal, and antifungal agent.3,7
CLASSIFICATION8
Kingdom    Animalia
   Phylum     Gelatinosa
     Class          Demospongia
        Subclass     Tetractinomorpha
       Order        Choristida
  Family       Jaspidae
    Genus       Jaspis
       Species    Jaspis splendens
Figure 2.1: Jaspis splendens.
Additional investigations revealed that jasplakinolide possessed potent
antihelminthic properties9 and caused dramatic changes in the cytoskeleton of plant cells.10
This compound also displayed potent antiproliferative properties in the NCI-60 cell line
screen.7b,11 Jasplakinolide is also active against tumor-derived cell lines, human prostate
carcinoma and myeloid leukemia.12 Furthermore, the drug is also active in vivo against
Lewis lung carcinoma and human prostate carcinoma xenografts.13 Exposure of cells in
vitro to jasplakinolide results in the formation of multinucleated cells. This prompted
further investigation of its biological properties.11b,14
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In the meantime, it was found that this compound has another use. It proved to be
an invaluable tool to probe cytoskeletal proteins and to observe the role of actin
microfilaments.15 The study explored a variety of cellular processes. Among these are: cell
movement, integrin-mediated adhesion, oocyte maturation, transport in the endocytic
pathways and protein trafficking in the Golgi apparatus.
In a study of the mechanism of action it could be shown that jasplakinolide exerts
its cytotoxic effect by sneaking into the cells. Then, it disrupts the actin cytoskeleton,
inducing actin polymerization. It also inhibits the depolymerization of actin filaments.
Other studies demonstrated that this cell-permeable drug not only potently induces actin
polymerization, but also competitively inhibits the binding of phalloidin to F-actin, thus
stabilizing filaments effectively.16
2.2 The Family of Jasplakinolide
Jasplakinolide presents as a new class of bioactive cyclodepsipeptides from marine
sponge. The derived structure as a 19-membered macrocyclic ring incorporates both
peptide and polypropionate portions. Besides the presence of the polyketide moiety, this
depsipeptide also bares two rare amino acids, β-tyrosine and 2-bromoabrine. The key
structural feature of cyclic depsipeptides is the replacement of an amide bond with an ester
bond. The most common modification includes N-methylation or extension of the carbon
chain. Aromatic amino acids such as tyrosine or tryptophan sometime contain ring
substituents like halides. While β-hydroxy acids can be traced back to the corresponding
α-amino acids, ω-hydroxy acids present in cyclic depsipeptides are made by the polyketide
machinery.
Geodiamolides A-F, which also includes geodiamolide TA and neosiphoniamolide,
are in the same family of jasplakinolide.17 These macrocyclic lactones share the same 11-
carbon polypropionate unit i.e., the 8-hydroxy-2,4,6-trimethyl-4-nonenoic acid (3a). They
differ structurally in the composition of the tripeptide portion. This is where the second
amino acid unit occurs as a variable monohalogenated N-methyl-L-tyrosine. The third
amino acid unit occurs as either L-alanine (geodiamolide A-C) or glycine (geodiamolide
D-E) (Figure 2.2). These related marine cyclodepsipeptide compounds show weaker
biological activity than jasplakinolide. For example, geodiamolide A and B are reported to
have weaker antifungal activity than jasplakinolide.18
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Figure 2.2: Structure of Jasplakinolide (1), Geodiamolides A-F, TA and
Neosiphoniamolide.
Due to the presence of the β-amino acid in jasplakinolide they also have different
ring sizes (19 vs. 18). It is not clear what the role of the individual building blocks is. The
tripeptide fragment might mimic a peptide or protein ligand. The 8-hydroxy acid could
function as a conformational control element involved in binding or not. Thus, akin to the
immunosuppressives FK506 and rapamycin,19 jasplakinolide could be a dual domain
molecule.
Irrespective of that, the ω-hydroxy acid is of interest from the viewpoint of
conformational control. The hydroxy acid 3a contains four methyl groups in a 1,3-distance.
One can identify two syn-pentane interactions and one 1,3-allylic interaction. The
consequence of the methyl groups is that the functional groups (carboxyl and hydroxy) at
both ends of the chain point in one direction and allow bridging with a peptide fragment.
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Based on the work of Hoffmann et al.,20 one can assume that the conformation of the chain
is largely determined by the central double bond and the three other methyl groups. While
definitely several low energy conformations are possible, an arrangement such as the one
depicted in Figure 2.3 should be accessible. This would still allow for an easy bridging.21
The conformation of the central part is governed by 1,3-allylic strain. The dihedral angles
of the single bonds next to the allylic system are gauche+ (60°) and gauche- (300°),
respectively. Since the hydroxy acid 3 is of great interest as a controlling element for the
orientation of bridging peptide fragments, we developed a novel synthesis for this
compound.
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hydroxy acid of jasplakinolide
eclipsed
CH3HH3C
H3C
H
OH
CO2H
CH3H
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1
4
6
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2,3 g+ 3,4 g+ 6,7 g- 7,8 g+
Figure 2.3: Possible conformation of the 8-hydroxy acid 3a due to the avoidance of CH3 -
CH3 steric interactions.
Soon after the recognition of the importance of jasplakinolide and geodiamolides,
many working groups around the world began to pursue synthesis strategies of polyketide
fragment 3a as the most important prerequisite. Two years after jasplakinolide was first
published, two groups announced the synthesis of 3a-like molecule. One of them has
finished the first total synthesis of jasplakinolide.22 To date, a fair amount of research has
already been carried out on the synthesis of the polyketide fragment. Other research also
exists in new total synthetic strategies forwards jasplakinolide and geodiamolides.
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2.3 Synthesis of Jasplakinolide
From a retrosynthetic standpoint, jasplakinolide can be viewed as consisting of four
distinct chiral subunits serially; protected hydroxy acid 3 and the protected constituent
amino acid fragments 4-6.
Scheme 2.1: Retrosynthetic pathway to jasplakinolide and tripeptide fragment.
Whereas protected (S)-alanine (6) is a commercially available compound, the
derivatives of (R)-β-tyrosine (4) and 2-bromoabrine (5) are required for the synthesis of the
tripeptide fragment 2. These two unusual amino acid derivatives can be synthesized from
available commercial starting materials by short routes.
Several syntheses of this metabolite have been reported.22a,23 However, within the
scope of the general introduction of this thesis, the synthesis of jasplakinolide and the
tripeptide are not the objective. Therefore, only a report that was published by the working
group of T. Momose is presented.23c
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2.3.1 β-Tyrosine Derivative
The β-tyrosine derivative can be prepared by multi-protection of the commercially
available L-4-hydroxyphenylglycine (7). The synthesis was started with the treatment of 7
with (Boc)2O in 0.5 N NaOH/dioxane (1:1). This was followed by the protection of the
phenolic hydroxyl group to obtain the silyl ether 8 in 46% yield. Subsequently, 8 was
treated with ethyl chlorocarbonate and followed by Arndt-Eistert’s procedure with
diazomethane to give the diazoketone 9 in 69%. The synthesis was continued by treatment
of 9 with silver benzoate in t-butanol in the presence of Et3N to produce the β-tyrosine
derivative 4 in 50% yield.
Scheme 2.2: The synthetic pathway to the protected β-tyrosine derivative (4).
The preparation of β-tyrosine derivatives by other short routes, such as from either
α-tyrosine, benzaldehyde or cinnamic acid derivatives is also possible.22a,23b,23d,24
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2.3.2 2-Bromoabrine Derivative
N-Boc-D-tryptophane (10) was initially used as a starting material for the route to
the bromide-tryptophan derivative portion. The N-atom on the aromatic ring was protected
by silylation with TBSCl followed by N-methylation to provide the completely protected
ester 11 in 88% yield. Desilylation with TBAF and subsequent bromination using NBS in
the presence of benzoyl peroxide provided the bromide derivative 5 in 90% yield.
Scheme 2.3: The synthetic pathway to the protected 2-bromoabrine derivative 5.
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2.3.3 Tripeptide Fragment
The synthetic pathway to obtain the tripeptide 2 started by selectively removing the
N-t-Boc group in β-tyrosine derivative 4 with TBSOTf in CH2Cl2 to give the free amine
12. The bromide tryptophan derivative 5 was hydrolyzed in 2N NaOH to give the
corresponding carboxylic acid 13. The coupling of 12 with 13 using DCC in the presence
of HOBT produced the dipeptide 14 in 75% yield. The cleavage procedure of the Boc
group was repeated in 14 with TBSOTf in CH2Cl2 to yield 15. The coupling of 15 with N-
Boc-L-alanine anhydride in CH2Cl2, in the presence of Et3N, and the subsequent treatment
with TBSOTf in the presence of 2,6-lutidine, gave the desired peptide 2 in 60% yield.
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Scheme 2.4: The synthetic pathway to the tripeptide fragment 2.
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2.3.4 Macrolactonization of Jasplakinolide
Jasplakinolide was synthesized by coupling of the tripeptide 2 and the
polypropionate segment 3 with 1.05 equivalents of DCC and HOBT in THF, to provide the
corresponding amide 16 in 81% yield. The cleavage of the t-butyl ester and partial
desilylation in 16 were effected simultaneously by treatment with TFA in dimethyl sulfide-
ethanedithiold-CH2Cl2 (3:4:20) at 0 °C, to give the hydroxy acid 17. The lactonization of
17 was accomplished by Yamaguchi’s procedure. Thus, treatment of 17 with 2,4,6-
trichlorobenzoyl chloride in benzene, in the presence of Et3N, followed by heating of the
mixed anhydride with DMAP under reflux, gave the 19-membered compound in 82%
yield. This reaction was followed by removal of the silyl group with TBAF in THF to
result in (+)-jasplakinolide (1) in 93% yield.
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Scheme 2.5: The synthetic pathway to jasplakinolide (1).
Similar preparation methods for a total synthesis of jasplakinolide (1) and the
tripeptide portion 2, including protected β-tyrosine 4 and bromide-tryptophan derivatives 5
have been reported.22a,24,23a,25
2.4 Synthesis of 8-Hydroxy-2,4,6-trimethyl-4-nonenoic acid
 The first synthesis of the polypropionate unit was reported in 1988, two years after
the discovery of jasplakinolide.3 The Grieco group announced the first total synthesis of
jasplakinolide. According to their strategy jasplakinolide was constructed from dipeptide
15 and the L-alanine-polypropionate unit derivative. In the same year the Schmidt group
reported the synthesis of this polypropionate unit as a precursor for the total synthesis of
jasplakinolide and geodiamolide A and B. Because the methodology to accomplish the
synthesis of this 11-carbon acid fragment has been extensively covered in literature, it is
not possible to give all the details in this thesis. An overview of some publications is
presented here to show the main reasons for undertaking this study.
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2.4.1 The Grieco Group’ s Strategy (1988)22a
The preparation of the 3b derivative began with iodolactonization of 18 as the
chiral starting material. The chiral acid 18 was readily available by resolution of the
racemic acid with (-)-α-methylbenzylamine in ether. Reduction and protection of the
primary hydroxyl group provided 19 in 63% yield. Conversion of the secondary hydroxyl
group to a methoxy methyl ether, followed by desilylation and oxidation, resulted in the
corresponding aldehyde 20. The aldehyde 20 was directly treated with 2-
propenylmagnesium bromide. The application of an ortho ester Claisen rearrangement to
the resulting allylic alcohol generated a rearranged ester 21. The ester 21 was hydrolyzed
and transformed into the N-acyloxazolidine 22. Alkylation of 22 with methyl iodide
resulted in the desired diastereomer (71%). The chiral auxiliary was removed to give the
corresponding carboxylic acid which was converted into the pyridinethiol ester 23.
Compound 23 was joined with the dipeptide 15 to give jasplakinolide.
Scheme 2.6: Synthetic pathway to the polypropionate moiety derivative by Grieco.
1. NaHCO3, I2, MeOH, H2O
HOOC
H
2. LiAlH4
3. TBDMSCl, Et3N
1. MOMCl, i-Pr2NEt
BrMg
CHO
2. LiAlH4
3. Swern oxidation
OPG
OH
OTBDMS
OPG
CO2Et2. CH3C(OEt)3, EtCO2H
1.
18
19
20 21
1. NaN(TMS)2, MeI
2. KOH
3. (PyS)2, Ph3P
PG = MOM-
OPG
S
O
N O
O O
N
iPr
22
23
OPG1. KOH
2. t-BuCOCl, Et3N
3. N-LiO
O
iPr
16 LITERATURE REVIEW
2.4.2 The Schmidt Group’s Strategy (1988)22b
 The synthetic route started with the alcohol 24 whose hydroxyl group was
protected and the functional group changed to the alkyl iodide 25. The asymmetric center
in the 6-position was constructed by diastereoselective alkylation of the hydrazone from
propanal, and (2R)-1-amino-2-methoxylmethyl-pyrrolidine with the 1-iodopropane
derivative 25. After cleavage of the hydrazone of 26 with ozone, the resulting aldehyde 20
was allowed to react with isopropenylmagnesium bromide to form the diastereomeric
allylic alcohols 27 and 28, in a ratio of 68:32. The quantitative separation of the
diastereomers was achieved by MPLC. The alcohols 27 and 28 were separately
esterificated to give 29 and 30 in 89% yield. The polyketide product 3b was achieved by a
Claisen ester enolate rearrangement.
Scheme 2.7: Synthetic pathway to the polypropionate moiety derivative by Schmidt.
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2.4.3 The White Group’s Strategy (1989)26
The preparation of the hydroxy acid moiety 3b started from (4S)-4-
methylbutyrolactone (32),27 obtained from (S)-propylene oxide (31). α-Methylenation of
the lactone 32 gave 33, which underwent hydrogenation to give (2R,4S)-cis-2,4-
dimethylbutylrolactone (34). Saponification of the lactone 34, followed by silylation, gave
35, which after reduction and oxidation provided the aldehyde 20. Treatment of 20 with
isopropenylmagnesium bromide furnished a mixture of diastereomeric allylic alcohols 27
and 28. These both reacted with triethyl orthopropionate in the presence of propionic acid
at 110 °C, producing a mixture of the ethyl esters 36. The mixture was separated by HPLC,
and subsequently hydrolyzed to give the acid fragment 3b.
Scheme 2.8: Synthetic pathway to the polypropionate moiety derivative by White.
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 2.4.4 The Momose Group’s Strategy (1989 and 1990)28
The ring-opening of (S)-propylene oxide (31) with the dianion of propionic acid,
gave a mixture of lactones 34 and 37, as a mixture of diastereoisomers (ca 1:1) in 62%
yield. Treatment of the mixture with LDA, and followed by protonation with (1R)-(-)-10-
camphorsulfonic acid resulted in 34 and 37 (ca. 6.6:1). The mixture was reduced with
DIBAL-H into lactols. The subsequent treatment of the resulting lactols with
propanedithiol and boron trifluoride etherate gave the 1,3-dithiane derivative 38 in 58%
yield along with its diastereoisomer in 8% yield. Silylation of 38 and oxidative hydrolysis
of the thioacetal group resulted in the aldehyde 20. Reaction of 20 with
isopropenylmagnesium bromide gave a 1:1 mixture of diastereoisomeric alcohols in 95%
yield. The mixture was converted to the desired isomer by Swern oxidation followed by
reduction of the enone with Red-Al to give alcohol 28 in 72% yield. The alcohol 28 was
then acylated with propionyl chloride. The resulting propionate 30 was subjected to an
enolate Claisen rearrangement to give the polyketide acid 3b in 77% yield, along with its
epimer in 6% yield. This route actually is quite similar to the one published by White et al.
Scheme 2.9: Synthetic pathway to the polypropionate moiety derivative by Momose.
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 2.4.5 The Konopelski Group’s Strategy (1991)25a
The reaction of 1822a with iodine in methanol-water containing sodium bicarbonate
produced the iodo γ-lactone which was subsequently dehalogenated to give the
corresponding lactone 34.29 The lactone 34 was reduced with DIBAL-H prior to treatment
with 2-lithio-2-propene. The resulting mixture of diol isomers 39 was directly subjected to
the Eschenmoser variation of the Claisen rearrangement, and gave, after basic hydrolysis,
the desired hydroxy acid along with the starting material. Protection of the secondary
hydroxy functionality gave its TBS-derivative 40 in 94% yield. Use of the Evans auxiliary
yielded 22. Asymmetric methylation of compound 22 proceeded to a 3:1 mixture of
isomers in 88% yield, separable by HPLC. The major isomer, obtained in 62% yield, was
transformed to the corresponding carboxylic acid 3b in 86% yield by treatment with
LiOH/H2O2.
Scheme 2.10: Synthetic pathway to the polypropionate moiety derivative by Konopelski.
2.4.6 The Kang Group’s Strategy (1991)30
Aldehyde 41 was prepared in three steps from ethyl (S)-(-)-lactate.31 (Z)-
Stereoselective Horner-Emmons olefination reaction of the aldehyde 41 with ethyl 2-
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(dimethylphosphono)propionate and KN(TMS)2/18-crown-6 gave the (Z)-unsaturated ester
42. The enoate 42 was treated with a catalytic amount of aqueous sulfuric acid (30%) to
yield 2-(5H)-furanone (43) in 84% yield from 41. Catalytic hydrogenation of 43 with
Rh/Al2O3 as the catalysts gave the lactone 34. Reduction of the lactone 34 with DIBAL-H
and subsequent Wittig homologation of the intermediate lactol with ethyl
(triphenylphosphorylidene)propionate, provided the trisubstituted olefin ester 44 in 64%
yield from 34. Conversion of 44 to 45 was achieved in 62% yield by protection of the
alcohol 44 with TBDPSCl, followed by DIBAL-H reduction and treatment with
phosphorus tribromide in the presence of pyridine. The allylic brmide 45 served then as an
electrophile in the alkylation of the enolate derived from N-[(4S,5S)-4-methyl-5-
phenyloxazolidinone]propionamide.
Scheme 2.11: Synthetic pathway to the polypropionate moiety derivative by Kang.
2.4.7 The Rama Rao Group’s Strategy (1993)32
This strategy uses the chiral (R)-2-methyl-4-pentenoic acid (48) as the building
block. The racemic mixture of 48 was prepared from diethyl methylmalonate (47). The
resolution of the racemic acid with L-phenylalaninol provided enantiomerically pure (R)-
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48. The iodolactoniaton of (R)-48 with I2-CH2CN provided the lactone 49 as a major
product, in 70% isolated yield. The lactone 49 was reduced with LAH to provide the diol
50. The primary hydroxyl group of diol 50 was temporarilly protected as a TBS ether,
while the secondary hydroxyl group was converted into the benzyl ether to give 51 (58%).
The deprotection of the silyl group and subsequent Swern oxidation yielded aldehyde 20.
Aldehyde 20 underwent a Wittig reaction, followed by reduction with DIBAL-H. The
resulting unsaturated alcohol 52 was further manipulated by epoxidation with MCPBA
leading to a single isomer. The hydroxyl group was converted to the corresponding iodo
derivative 53. The reductive elimination of the iodide 53 was followed by acylation with
propionyl chloride to result in the propionate 30. The acid 3b was obtained from Ireland-
Claisen rearrangement of 30.
Scheme 2.12: Synthetic pathway to the polypropionate moiety derivative by Rama Rao.
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2.4.8 The Shioiri and Hamada Group’s Strategy (1994 and 1997)17,25b
Commercially available (2S,4S)-2,4-pentanediol (54) was subjected to
monosilylation with TBSCl, followed by tosylation with TsCl, resulting in the tosylate 55.
The reaction of the tosylate 55 with lithium cyanide in HMPA, afforded the cyanide 56 in
good yield. This was accompanied with inversion of configuration. The reduction of the
cyanide, followed by a Wittig reaction, yielded the (E)-unsaturated ester 57. The ester was
converted to the alcohol 52 with DIBAL-H in good yield. The replacement of the hydroxyl
group with an iodide (I2, imidazole, PPh3, CH3CN) quantitatively produced the photolabile
iodide. The Evans asymmetric alkylation of the sodium enolate from the oxazolidinone
with the iodide, gave the alkylated product 58 with a high diastereoselectivity (E:Z=96:4).
Removal of the chiral auxiliary was easily achieved with lithium hydroxide-hydrogen
peroxide to give the required polyketide 3b, in an overall yield of 34% in 9 steps.
Scheme 2.13: Synthetic pathway to the polypropionate moiety derivative by Shioiri and
Hamada.
An alternative strategy was published by the Kocienski group (1995).23d They used
a 1,2-metallate rearrangement of a metallated dihydropyran and a metallated enol
carbamate derivative, as the key steps in the synthesis of the polyketide fragment 3b. This
route unfortunately gave a low yield of the desired product over many steps.
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2.5 Critical Review and Reason for Undertaking This Study
Since the first publication of the synthetic pathway to the polypropionate unit 3b in
1988 till this project began in 2001, various approaches to obtaining large-scale supplies of
polyketide fragment 3 have been considered to construct either jasplakinolide or
geodiamolides. In most of these approaches, the aldehyde 20 served as a key building
block. For the extension of the carbon chain, the combination of the Grignard reaction with
2-propenylmagnesium bromide followed by a Claisen rearrangement is used frequently.
Alternatively, the tactical sequence of a Wittig reaction followed by conversion to an
allylic halide and asymmetric alkylation has been employed. The contribution of these
approaches to the development of new methodologies and synthetic strategies has provided
a large and valuable addition to synthetic methodology. In comparing the various routes,
the synthesis of Shioiri (Scheme 2.13) appears to be the most efficient route so far. It
requires less steps, produces high yield and high selectivity. However, this strategy
requires expensive starting materials. In addition, the end game that means the steps from
alcohol 52 to the acid 3b in the Rama Rao work appears to be highly original. Some other
routes are too complicated to be utilized for large-scale production. An example is the
requirement of MPLC or HPLC for the purification step. The remaining routes produce the
desired acid 3 in low stereoselectivity or low yield over many steps of reaction.
2.6 Goal of Research
Jasplakinolide displays very interesting properties and is also used as an important
biochemical tool. Although several syntheses of this metabolite had been reported when
this project began, there were no reports where variations had been performed. This
metabolite is ideally suited for modification due to its modular structure. Jasplakinolide is
composed of the structural combination of the hydrophobic polypropionate and polar
peptide chains. The interest for the construction of jasplakinolide, as well as others in the
family of these novel biologically-active macrocycles, lies in the synthesis of the
polypropionate fragment. While several syntheses of the acid moiety have been reported,
they are still far from being economical and are unlikely to become a solution to the supply
problem of jasplakinolide. This is why the preparation of the 8-hydroxy-2,4,6-trimethyl-4-
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nonenoic acid (3a), the so-called “8-hydroxy acid of jasplakinolide” is an attractive
although challenging option.
Consequently, the objective of this study is the development of a simpler procedure
for the synthesis of the acid fragment and acid-like molecules, while attempting to find the
most efficient of the methods. The discovery of a practical and useful new strategy requires
that the key idea meets three important criteria:
1. The strategy should be “makeable or scaleable”. In other words, the reaction must take
place easily with high stereoselectivity, high yield and absence of special requirements.
It must also be able to provide the final target molecule in large scale production.
2. It must be practical. The reaction protocol must involve commercially available starting
materials, reactants and catalysts which are inexpensive.
3. It must allow for easy modification and be applicable for the preparation of
stereoisomeric and structural analogues. This means it must involve efficient
enantioselective reactions to generate each of the stereo centers independently, offering
maximum flexibility.
The approach is based upon the assumption that organic synthetic study is not
merely the knowledge of how to approach the target molecule, but also to find simple
solutions to complex synthetic problems. Frequently this leads to the discovery of new
strategies, reagents, and reactions. This potentiality can be of great benefit to society.
In this study, the 8-hydroxy acid 3b and analogues were investigated in order to
couple with the tripeptide moiety, involving the total synthesis of jasplakinolide and
jasplakinolide-like molecules.
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3 RESULTS AND DISCUSSION
3.1 Retrosynthetic Analysis
From a retrosynthetic standpoint, one has to address the three chiral centers and the
double bond configuration. The strategy underlying the synthetic plan was to apply
efficient enantioselective reactions to generate each of the stereochemical centers
independently. This would offer flexibility for the preparation of stereoisomeric and
structural analogues. Moreover, the starting material should be cheap.
It is anticipated that the isolated C2 stereocenter could be fashioned efficiently by
employing an asymmetric Evans alkylation. The highly enantioselective induction is the
reaction between enolates that are derived from an appropriate oxazolidinone and an alkyl
halide precursor. Following previous publications, our plan was also designed to introduce
the C2 stereocenter at a late stage of the synthesis. Cleavage of the C4-C5 olefin bond
results in two allyl fragments. The union of these two moieties may be envisaged either via
a Wittig conjugated system or metathesis coupling. Construction of the chiral center C6
would present a challenging test to state-of-the-art techniques either from asymmetric
cyclopropanation methodology followed by ring opening, or from diastereoselective
methylation on a ring system. The secondary alcohol at the C8 stereocenter, although it is
certainly not obvious, could be installed by either selective alkylation of the aldehyde, or
conversion from the corresponding ketone. All approached strategies for the synthesis of
the polypropionate unit opted to build C8 as a primary stereocenter. The synthetic plan as
discussed in the retrosynthetic pathway is shown in Figure 3.1.
CO2H
TBSO
24
5
68
(3b)
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Figure 3.1: Structure and Retrosynthetic Analysis of (2S,4E,6R,8S)-8-hydroxy-2,4,6-
trimethylnon-4-enoic acid (3a) derivatives.
In this study, the approached strategies are divided into routes A, B, C and D,
according to the four different methods used to build the chiral C8 at the beginning of the
strategy.
3.2 Synthetic Pathway to the 8-Hydroxy Acid of Jasplakinolide
 -ROUTE A
In our initial retrosynthetic analysis for the construction of the required target
molecule four key reaction steps were planned. They are an asymmetric reduction of ethyl
acetoacetate (64) by yeast for formation of the first chiral center C8, then a Charette
method: an asymmetric cyclopropanation of the double bond followed by ring opening for
introducing a methyl group at C6, then a Wittig reaction for formation of the double bond
at C4-C5 which would take place after the reductive opening of an (iodomethyl)
cyclopropane, and an Evans alkylation as a means of stereoselective introduction of the last
methyl substituent into this system at C2. The sequence leading to the 8-hydroxy-2,4,6-
trimethylnon-4-enoic acid derivative (3b) is shown in Scheme 3.1.
CO2H
R1
R2
HO
24
5
68
a) alkylation from aldehyde
b) reduction from ketone
a) methylation
b) cyclopropanation
    and ring opening
a) Wittig reaction
b) metathesis
alkylation
R1 = alkyl
R2 = alkyl
CO2H
PGO
(3b)
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Scheme 3.1: Retrosynthetic analysis of (2S,4E,6R,8S)-8-{[tert-Butyl(dimethyl)silyl]oxy}-
2,4,6-trimethylnon-4-enoic acid (3b).
Key Reactions and Mechanisms
3.2.1 Bakers’ Yeast Enantioselective Reduction
Saccharomyces cerevisiae is commonly known as "bakers’ yeast" or "brewers’
yeast".33 The yeast ferments sugars present in the flour or added to the dough, giving off
carbon dioxide (CO2) and alcohol (ethanol). For organic chemistry bakers’ yeast is an
interesting biocatalyst, which is easily accessible in the laboratory and can catalyze highly
enantioselective reductions.34
Bakers’ yeast is able to reduce variously substituted carbonyl groups to the
corresponding hydroxy compounds. The source of the hydride is basically glucose-6-
phosphate. The stereochemical outcome of these reactions generally follows the so-called
Prelog’s rule35 and leads to the (S)-alcohols (Scheme 3.2).
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G6P:  glucose-6-phosphate
GL6P: glucono-δ-lactone-6-phosphate
G6PDH: glucose-6-phosphate dehydrogenase
NADP+: β-Nicotinamide-adenine dinucleotide phosphate
NADPH:β-Nicotinamide-adenine dinucleotide phosphate, reduced
Scheme 3.2: Asymmetric reduction of carbonyl compounds mediated by bakers’ yeast.34b
β-Ketoesters are one of the thoroughly studied carbonyl compounds and generally
react with good enantioselectivity, depending on the volume of substituents. In this family
of compounds, Prelog’s rule is suitable for predicting the selectivity in the event of a
change of substituents. A decrease in the size of R1 and an increase in the size of R2
generally enhance L-selectivity, while a bulkier R1 shifts reduction in favor of the D-
enantiomer (Scheme 3.3).
Scheme 3.3: Change of enantioselectivity as depending on the volume of R1 and R2.34a
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Table 3.1: Enantioselective preparation of some β-hydroxy esters from the corresponding
β-keto esters by baker’s yeast reduction.34b, 36
Entry R1 R2 Yield (%) ee (%)a
1
2
3
4
5
6
Me
Me
Me
Me
Et
n-Bu
Me
Et
n-Bu
t-Bu
Et
Et
49
57-76
58
61
67
-
97
84-87
90
85
- 40
- >90
Note: a) The values for entries 5 and 6 are listed as negative numbers because baker’s yeast
reduction yields the opposite enantiomer as the major product.
3.2.2 Enantioselective Cyclopropanation of Allylic Alcohols
A reaction between iodomethylzinc iodide and an olefin that produces a
cyclopropane compound was first reported by Simmons and Smith. It is now called the
Simmons-Smith (SS) reaction.37 The iodomethylzinc iodide as the original Simmons-Smith
reagent was prepared from CH2I2 and metallic zinc. The modification, wherein the
insoluble zinc-copper couple is replaced by diethylzinc, is used widely in organic
synthesis. The new reagent can provide better reproducibility, greater substrate variety, and
faster reactions.38
The addition of suitable chiral ligands to the SS reaction leads to the asymmetric
synthesis of cyclopropanes.39 These chiral auxiliaries have been divided into two classes.
They are the zinc-based carbenoid reagents and the transition metal-based carbenoid
reagents. There are numerous auxiliary-based methods such as tartrate-derived acetal 65,
disulfonamide 66, and dioxaborolane 67. These catalysts generally provide high levels of
diastereoselectivity.40
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Figure 3.2: Structures of acetal 65, disulfonamide 66, and dioxaborolane 67.
The SS reagents with an allylic alcohol have distinct advantages over the reaction
with a simple olefin with regard to the reaction rate and stereocontrol.41 Much of the
development of enantioselective zinc-based cyclopropanation has relied upon the effect of
an allylic alcohol functional group to provide a locus for reagent tethering and control.42
The use of stoichiometric quantities of chiral additives to modify the reagent has also met
with considerable success.43 Among this type of reaction, dioxaborolane 67 is a notable
example.
Figure 3.3: Transition state model for cyclopropanation of allylic amide 67.44
The use of a stoichiometric quantity of the chiral dioxaborolane 67 with allylic
alcohol leads to the formation of cyclopropanes in high yield and high enantiomeric
excess. The iodomethylzinc reagent, which is formed in situ by the reaction of diethylzinc
and diiodomethane, interacts with the chiral dioxaborolane enabling the synthesis of
enantioenriched cyclopropanes.
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Scheme 3.4: Charette asymmetric cyclopropanation with the chiral catalyst 67.45
3.2.3 Cross Metathesis (CM)46
Olefin metathesis is a powerful method for the formation of carbon-carbon double
bonds.47 It can be described as a reaction in which all the carbon-carbon double bonds in an
olefin (alkene) are broken and then rearranged in a statistical fashion (Scheme 3.5). If one
of the product alkenes is volatile (such as ethylene) or otherwise easily removed, the
reaction shown below can be completely driven to the product side.
Scheme 3.5: Cross metathesis reaction.48
Grubbs49 and others50 have broadened the scope of olefin metathesis and done
extensive mechanistic work for the improvement of defined substrate and functional group
tolerant ruthenium based metathesis catalysts. The activity of the “first-generation”
ruthenium metathesis catalyst (68) was significantly improved with the “second-
generation” catalyst (69) where an N-heterocyclic carbene replaces one phosphane
group.49,50a-b Both first and second generation Grubbs catalysts were studied in this project.
As a general consideration for the ranking of olefin reactivity in CM, olefins can be
categorized according to the products they give with the two Grubbs catalysts. In this
regard, olefins can belong to one of these four categories.48
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Ru
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Grubbs II catalyst  (69)
Grubbs I catalyst  (68)
Ru
H
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Cl
Cl
PCy3
PCy3
Table 3.2: Reactivity of alkenes with first and second generation Grubbs catalysts.48
Olefin
Type
Type I Terminal olefins, allyl silanes,
1° allylic alcohols, ethers,
esters, allyl boronate esters,
allyl halides
terminal olefins, 1° allylic alcohols, esters,
allyl boronate esters, allyl halides,
styrenes (no large ortho substituted), allyl
phosphonates, allyl silanes, allyl
phosphine oxides, allyl sulfides, protected
allyl amines
Type II styrene, 2° allylic alcohols,
vinyl dioxolanes, vinyl
boronates
styrenes (large ortho substituted),
acrylates, acrylamides, acrylic acid,
acrolein, vinyl ketones, unprotected 3°
allylic alcohols, vinyl epoxides, 2° allylic
alcohols, perfluorinated alkane olefins,
Type III vinyl siloxanes 1,1-disubstituted olefins, non-bulky
trisubstituted olefins, vinyl phosphonates,
phenyl vinyl sulfone, 4° allylic carbons
(all alkyl substituents), 3° allylic alcohols
(protected)
Type IV 1,1-disubstituted olefins,
disub. α,β-unsaturated
carbonyls, 4° allyl carbon-
containing olefins,
perfluorinated alkane olefins,
3° allyl amines (protected)
 vinyl nitro olefins, trisubstituted allyl
alcohols (protected)
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The Proposed Rules (Guidelines)48
Type I: rapid homodimerization, homodimers consumable.
Type II: slow homodimerization, homodimers sparingly consumable.
Type III: no homodimerization.
Type IV: olefins inert to CM, but do not deactivate catalyst (Spectator)
Rule:
reaction of two alkenes from Type I: statistic CM
reaction of two alkenes from same Type (non-Type I): nonselective CM
reaction of two alkenes from different Type: selective CM
The mechanism for olefin metathesis by ruthenium carbene catalysis is consistent
with Chauvin's metallacyclobutane mechanism.51 The principal steps involve the initial
dissociation of a (phosphane) ligand from the 16 valence electron (VE) starting complex A
to form the 14 VE active species B. After ruthenium had less coordination, a transition
metal carbene forms π complex C by coordination of an olefin. The metallacyclobutane
intermediate D is then obtained by a formal [2+2] cycloaddition. After the [2+2]
cycloreversion, the olefin product is released from the olefin π complex E. The 14 VE
active species F can either re-enter into the catalytic cycle or be trapped by a phosphane
(complex G).
Scheme 3.6: Mechanism of olefin metathesis.52
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3.2.4 Stereoselective Enolate Alkylation
The versatile oxazolidin-2-one based chiral auxiliary methodology was first
developed by Evans et al.53 The auxiliaries are easy to prepare from α-amino acids. For
instance chiral oxazolidin-2-ones 70-73 are available from valine, phenylalanine,
phenylglycine, and norephedrine, respectively.54
The auxiliary has been utilized in a wide variety of synthetic transformations such
as asymmetric aldol condensation, stereoselective alkylation, stereoselective differentiation
of enantiotopic groups in molecules bearing prochiral centers, and other interesting
applications.55 For example, it has been widely used for the asymmetric synthesis of
homochiral α-substituted carboxylic acids.56
Scheme 3.7: Synthesis of homochiral α-substituted carboxylic acids using oxazolidin-2-
one chiral auxiliaries.57
In this study, N-acyloxazolidin-2-one 75 derived from D-phenylalanine (74) was
employed to control the asymmetric alkylation of enolate.58 The enolization of imide 75
with NaN(SiMe3)2 is known to generate a Z-enolate 76.59 The sodium enolate 76 comprises
two distinct p-faces (re and si face) because the sodium ion coordinates to both the N-acyl
and the oxazolidinone carbonyl oxygens. The si-face is difficult to access for electrophiles
because of the steric hindrance of the aromatic substituent as shown in Figure 3.4.  
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Figure 3.4: Transition states of the Evans alkylation.55b,60
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Synthetic Pathway
The first synthetic pathway started by yeast reduction of acetoacetate 64.36 (see
3.2.1 Bakers’ Yeast Enantioselective Reduction) Two types of yeast were studied for
building the first chiral center under both aerobic and anaerobic conditions as shown in
Table 3.3.
Table 3.3: Studies on baker’s yeast reduction.
Entry Baker’s Yeast Condition Yiled (%) ee (%)d
1
2
3
4
Fresha
Fresha
Powderb
Powderb
Aerobic
Anaerobicc
Aerobic
Anaerobicc
73
32
14
52
89
91
59
84
Note: a) Backhefe DHW Vital Gold; Deutsche Hefewerke GmbH & Co. ORG Nürnberg
b) RUF Hefe, RUF; Lebensmittelwerk KG D-49610 Quakenbrück.
c) The reaction was performed in an erlenmeyer flask with bubble counter.
d) The enantiomeric excess values (ee) were measured by GC.
The fresh baker’s yeast under aerobic condition (entry 1), which gave the best
result, was selected for the synthesis of the chiral 3-hydroxy ester 63. A subsequent
silylation of the hydroxy ester with tert-butyl-dimethylsilyl chloride (TBSCl) in the
presence of imidazole gave the known compound 78.61 Reduction with
diisobutylaluminium hydride (DIBAL-H) provided the aldehyde61a,62 79 that was converted
to the enoate63 62 by reaction with the stabilized Wittig reagent (Ph)3P=CHCO2Me (80).64
Reaction of the enoate 62 with 2.2 equivalents of DIBAL-H furnished the allylic alcohol
81.65 In order to introduce a methyl group at position C6 of the target hydroxy acid 3 we
used the reductive opening of an (iodomethyl)cyclopropane. Accordingly, the allylic
alcohol was converted to the hydroxymethylcyclopropane 61 using a combination of
Me
O
Baker's yeast
64 63
O
O
Et
Me
O
O
Et
OH
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diiodomethane, diethylzinc and the chiral dioxaborolane 67 (Charette method).42 (see 3.2.2
Enantioselective Cyclopropanation of Allylic Alcohols) Since a direct conversion of the
primary alcohol to the corresponding iodide (I2, imidazole, PPh3, CH3CN) was not a clean
reaction, the pathway via the mesylate 82 was followed. Treatment of the mesylate 82,
obtained from the alcohol 61 with mesyl chloride and triethylamine, with NaI in acetone
gave the iodide 83 in excellent yield.66 The reductive ring opening67 of 83 was achieved
with n-butyllithium in THF between -78 and -30 °C resulting in the alkene 60 with 73%
yield. According to the 13C NMR spectrum, this compound was diastereomerically pure (>
98%).
Scheme 3.8: Synthesis of the key building block 60.
OR
CO2Et
TBSO
O
B
O
Me2NOC CONMe2
Bu
OTBS
CHO
OTBS
CO2Me
OTBS
OH
79
62 81
67
CO2Et
O
Baker's yeast
73% yield
64
 89% ee
TBSCl, imid.
      100%
100%
DIBAL
63  R = H
78  R = TBS
96%
DIBAL Et2Zn, CH2I2, 67
      96% yield, 98% de
CH3SO2Cl, NEt3
NaI, acetone
96% from 61
82  R = OMs
83  R = I
TMEDA, MS 4 Å, n-BuLi
 73%
60
80
80
(Ph)3P CO2Me
97%
OTBS
OH
61
OTBS
R
38 RESULTS AND DISCUSSION
The preparation of the dioxaborolane ligand 67 as a chiral auxiliary for
cyclopropanation began with (2R,3R)-2,3-dihydroxy-N,N,N′,N′-tetramethylsuccinamide
85.68 The succinamide 85 was prepared from (L)-diethyl tartrate (84) as the chiral starting
material.69 The Grignard reaction of trimethyl borate (86) with butylmagnesium bromide
followed by hydrolysis with 10% hydrochloric acid afforded butylboronic acid (87) in 74%
yield. The butylboronic acid was treated with diethanolamine in the presence of molecular
sieve 3Å to afford 2-butyl-1,3,6,2-dioxazaborocane (88). The dioxazaborocane 88 was
stirred with the previously prepared succinamide 85 under inert atmosphere at room
temperature to give the chiral auxiliary 67.
Scheme 3.9: Synthesis of the chiral auxiliary 67.
For the extension of the alkene 60 to the enoate 91 we initially used the sequence of
ozonolysis and Wittig reaction.70 The Wittig reaction of the resulting aldehyde 20 with the
stabilized ylide71 90 yielded the enoate ester 91. However the ozonide 89 proved to be
rather stable and its reductive cleavage with dimethyl sulfide (2 mL/mmol of 60) in CH2Cl2
required stirring for 1 week. The one-pot cleavage and Wittig-reaction also did not work.72
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Scheme 3.10: Synthesis of the enoate 28 by Wittig reaction from key building block 60.
Therefore we opted for the direct conversion of the alkene 60 to the enoate 91 by
alkene cross metathesis.48 (see 3.2.3 Cross Metathesis) We set out to study first the
reactivity of the alkene 60 with methyl methacrylate (92) in the presence of the Ru-based
catalysts 68 or 69 in CH2Cl2 (Table 3.4).
TBSO
O
60 O O
TBSO
O
TBSO
CO2Me
89 20
91
O3 Me2S
97% from 8
90
TBSO
20 82%, E/Z = 3:1
90
(Ph)3P CO2Me
90
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Table 3.4: The preliminary study for the cross-metathesis of the alkene 60.
Entrya Catalyst Solvent Temperature (°C) Alkene 92 (eq.) Yield 91b (%)
1
2
3
4
5
68
69
68
69
69
CH2Cl2
CH2Cl2
CH2Cl2
CH2Cl2
toluene
40
40
40
40
70
1.5
1.5
20
20
10
traces
30
traces
51
48
Note: a) Reaction performed on a small scale.
b) E isomer exclusively.
A preliminary experiment was carried out with 5 mol% of the ruthenium catalyst
68, 1 equivalent of the alkene 60 and 1.5 equivalents of methyl methacrylate (92). The
reaction took place under reflux at 40 °C in CH2Cl2. We found that under these conditions
the desired product 91 was only obtained in traces (entry 1). In the presence of catalyst 69,
the reaction afforded the desired compound in 30% yield (entry 2). Afterwards the
reactions were performed, under the same conditions, in the presence of catalyst 68 and an
excess of methyl methacrylate (20 equivalents). Under these conditions the CM product 91
was again only obtained in traces (entry 3). In the presence of catalyst 69 the reaction
yielded the desired product in 51% yield (entry 4).
The Ru-based catalyst 68 always provided the enoate 91 only in traces. Therefore,
we opted to use Grubbs II catalyst 69 for alkene cross metathesis of the olefin 60 with
methyl methacrylate (92). For the best production of the desired compound 91 with 5
mol% of the Grubbs II catalyst (69), the proper reaction conditions were sought.
TBSO
CO2Me
91
TBSO
60 68 or 69 (5% mol)
CO2Me
69
Ru
H
Ph
Cl
Cl
PCy3
NNMes Mes
68
Ru
H
Ph
Cl
Cl
PCy3
PCy3
92
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Olefin cross-metathesis (CM) is a thermodynamically controlled reaction that is
complicated by statistical product distributions and a mixture of olefin stereoisomers.
During the course of this preliminary study we also assessed the reactivity of methyl
methacrylate (92) towards alkene 60 in different solvents and at different temperatures.
The reactions were performed in toluene at 70 °C in the presence of catalyst 69. Under
these conditions the CM product 91 was isolated as a single stereoisomer (E only) in 48%
yield (entry 5). This result is a similar to those obtained in CH2Cl2 at 40 °C (entry 2 and 4).
In the preliminary experiment the dimer of 60 from homodimerization was
observed as the side product of cross metathesis. In order to achieve a higher cross
metathesis product yield, the conversion of the starting material 60 into the cross-
metathesis product 91 was explored with 1 equivalent of the alkene 60 combined with
several equivalents of methyl methacrylate (92) in the presence of 5 mol% of catalyst 69.
The results are listed in Table 3.5.
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Table 3.5: Optimization study for the CM of alkene 60 based on equiv. of alkene 92.
% YieldEntry Equiv. of
Methyl methacrylate Product 91 Dimer of 60 Combined yield
1
2
3
4
5
                 1.5
5
10
15
20
30
43
73
55
51
56
42
17
23
10
86
85
90
78
61
The use of only 1.5 equivalents of methyl methacrylate (92) resulted in the
formation of only 30% of product 91 along with 56% of homodimerisation of 60 (entry 1).
The reaction with an excess amount of methyl methacrylate (92) resulted in less
homodimerisation of the alkene 60 and more of the desired cross-metathesis product 91
(entries 2 and 3). Particularly noteworthy is the result of the reactions using higher excess
of methyl methacrylate (92) that provided less of the desired CM product 91 (entries 4 and
5). Indeed a 73% yield of the CM product 91 was attained by reacting compound 60 with
10 equivalents of 92 in the presence of 5 mol% of catalyst 69. Only 55 and 51% yields of
the CM product 91 were observed when alkene 60 was reacted with 15 and 20 equivalents
of 92 respectively.
Accordingly optimal results were obtained by performing the reaction of the alkene
60 and 10 equivalents of methyl methacrylate (92) in CH2Cl2 under reflux at 40 °C with 5
mol% of Grubbs catalyst 69.
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Scheme 3.11: Synthesis of the enoate 91 by cross coupling metathesis from olefin 60.
The dimer of 60, a by-product from the study, was recovered by ozonolysis70 back
to compound 89, followed by transformation shown in Scheme 3.10. The remaining steps
to the desired acid were performed in a similar way as described in literature. Thus,
reduction of ester 91 to alcohol 93, followed by conversion to the allylic mesylate 94 and
substitution of the mesylate with iodide delivered the iodide 59 in good overall yield for
the three steps.17,30 Besides the mesylate 94, the corresponding allylic chloride 95 is also
formed in a yield of less then 10%. For analytical purposes the mesylate and chloride were
separated, however the mixture can be used as such for the next step. The iodide 59 was
then used as the electrophile in an Evans alkylation59 with the propionyloxazolidinone 75.58
(see 3.2.4 Stereoselective Enolate Alkylation) The absolute configuration of the alkylation
product 96 was determined by a final hydrolysis of the alkylation product 96 to the known
TBS-protected hydroxy acid 3b in quantitative yield.17,22,23a-b,d,28b,30,32
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Scheme 3.12: Synthesis of hydroxy acid 3b from the alkene 60.
The carboximide 75 as a chiral auxiliary for alkylation was prepared from D-
phenylalanine.58 The preparation began with a direct reduction of (R)-phenylalanine (74)
with borane. The resulting amino alcohol 97 was transformed into oxazolidinone 98 by
condensation with diethyl carbonate in the presence of catalytic amounts of potassium
carbonate. Further deprotonation with n-butyllithium and subsequent acylation with
propionyl chloride afforded the desired propionyloxazolidinone 75 in good overall yield
for the three steps.
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Scheme 3.13: Synthesis of the chiral auxiliary propionyloxazolidinone 75.
After successfully synthesizing 3b, an improvement of the strategy was explored.
Since the cross metathesis combines two alkenes, it offers the possibility of a shorter
synthesis. Ideally the completed right part might be connected to alkene 60. (see 3.2.3
Cross Metathesis) Thus, some terminal 2-methyl olefins were arranged for a
demonstration.
The chiral propionyloxazolidinone 75 was treated with 3-bromo-2-methylpropene
(99) in an Evans alkylation59 to provide the olefin73 100. (see 3.2.4 Stereoselective Enolate
Alkylation) The alkylated product was converted to alkenes 10174, 10275 and 10376. Further
silylation of the alcohol 103 with tert-butyl-dimethylsilyl chloride (TBSCl) in the presence
of imidazole provided the TBS-protected alkenol76d 104 in quantitative yield.
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Scheme 3.14: Preparation of the chiral 2-methyl olefins 100-104 from oxazolidinone 75.
The first idea was to try the coupling of alkene 60 with acid 102 via metathesis with
Grubbs catalyst II (69) to directly yield the final product 3b. Unfortunately, there was no
reaction. At the end of the procedure, only a mixture of two starting materials (60 and 102)
was present. The result could be anticipated because the carboxylic group of olefin 102
might deactivate the Grubbs catalyst. The next attempt took a step back to compound 96 by
coupling of alkene 60 with olefin 100. After a couple experiments, the observed products
were only the dimer of 60 and the starting material 100. This failed synthesis might be
caused by the low reactivity of alkene 100. According to Table 3.2 alkenes 100-104 are
type III olefins with Grubbs II catalyst and probably show a low inherent reactivity.
Afterwards an intensive investigation of metathesis cross coupling of alkene 60
with four different 2-methyl allyl compounds (101, 103, 104 and 99) was performed. After
several attempts under different conditions, more surprising results were observed. In all
reactions, only a mixture of alkene 60, the starting 2-methylallyl compound, and the dimer
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of 60, but none of the desired product was observed. This result indicates that the
formation of the desired product via cross coupling metathesis technique requires a suitable
2-methyl-olefin, which might need to have an electron withdrawing substituent. According
to our study only methyl methacrylate (92) was a possible candidate.
Scheme 3.15: Metathesis of the alkene 60 with various olefins (99-104).
Thus, the synthesis via route A resulted in over 2 grams of 3b in 20% yield over 15
reaction steps from the acetoacetate 64. This approach could possibly allow for the
preparation of other analogues of the target molecule.
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CO2HR
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3.3 Alternative Approach to 8-Hydroxy Acid and Derivatives
                                                       ≠
Route A could be an excellent methodology for the production of 3b. However, the
scope of biochemical methods using yeast reduction is limited, because of the inherent
single-handed, lock-and-key specificity of biocatalysts. For the required chiral
configuration at C8, yeast reduction of β-keto ester could furnish only a substituted methyl
group.36 (see 3.2.1 Bakers’ Yeast Enantioselective Reduction)
Asymmetric catalysis is an integrated chemical approach where the maximum
chiral efficiency can be obtained by a combination of suitable molecular design and proper
reaction conditions. The use of chiral organometallic molecular catalysts is a powerful
strategy for this purpose. They allow for the flexible synthesis of a wide array of
enantiopure organic substances from achiral precursors. Figure 3.6 illustrates an ideal way
for multiplying molecular chirality.77 A small amount of a well-designed chiral catalyst can
combine A and B, producing the chiral AB product stereoselectively in a large quantity.
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Figure 3.5: A general principle of asymmetric catalysis with chiral organometallic
molecular catalysts.
The chiral ligands are enantioselective over a wide range of different reactions.
They possess suitable three-dimensional structures and functionality to generate sufficient
reactivity and the desired stereoselectivity. One can illustrate that these chiral ligands
create effective asymmetric environments for mechanistically unrelated reactions. There
are certain classes of synthetic catalysts that modify intrinsically achiral metal atoms. This
group of special chiral ligands and catalysts shows high selectivity for example, BINAP
and BINOL, bis(disulfonamide) ligands, tartaric acid derivatives, derivatives of the
cinchona alkaloids, and chiral salen ligands (Figure 3.6).78
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Figure 3.6: Examples of privileged chiral ligands and catalysts.
In this part of the research program, asymmetric processes catalyzed by
organometallyic complexes were explored in order to allow more flexibility to get the
stereoisomeric analogues of the 8-hydroxy acid (3). Simpler tactics that mimicked the
former approach were designed. The alternative preparation of hydroxy acid 3 and
analogues was demonstrated with three different synthesis methodologies as follows:
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-ROUTE B
The first plan was based on the Noyori reduction of β-ketoesters 64. This reaction
provides secondary alcohols of type 63 usually in high enantiomeric purity.79 The further
process could be performed similar to the procedure from route A.
Scheme 3.16: Retrosynthetic analysis for the synthesis of 8-hydroxy nonenoic acid
derivatives starting with Noyori reduction of a β-ketoester.
Key Reactions and Mechanisms
3.3.1 Asymmetric Hydrogenation of β-Keto esters
BINAP, 2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl, is a chiral ligand commonly
used in the formation of catalytic reagents. This catalyst ligand is a fully aromatic and
conformationally flexible atropisomeric C2 diphosphine. Because rotation about the
binaphthyl C1-C1' pivot and C2- or C2'-P bonds is possible without seriously increasing
the torsional strain, it can accommodate a range of transition metals, mainly of the second
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and third rows, such as Ru(II), Rh(I), palladium and iridium.80 The axially dissymmetric C2
chiral diphosphine exerts strong steric and electronic influences on transition metal
complexes. The resulting seven-membered chelate rings containing only sp2 carbon atoms
are in turn skeletal structures.80,81 Many of these species promote various asymmetric
transformations such as hydrogenation, isomerisation, hydrosilylation, hydroboration and
allylic alkylation.
 BINAP-Ru dichloride catalysts have a very wide scope for the hydrogenation of β-
keto esters.81 The halide ligand in the Ru complex generates a strong acid HCl and an
active species RuHCl, formed by the reaction between Ru complex A and H2.82 These
species are important to facilitate the hydride transfer from Ru to the carbonyl carbon
(Scheme 3.17).83
The Scheme presents a mechanistic model for (S)-(diphosphine)Ru-catalyzed
hydrogenation of β-keto esters. First, B interacts reversibly with the β-keto ester to form
the σ-type chelate complex C, in which metal-to-carbonyl hydride transfer is geometrically
difficult. Then, protonation occurs at the oxygen to increase the electrophilicity of the
carbon and convert the geometry from σ  to π, thereby facilitating the hydride migration.
The hydroxy ester ligand complex in the resulting product D is liberated by solvent
molecules. The cationic Ru complex E once again cleaves H2, thus regenerating B. This
catalytic cycle takes place repeatedly. Enantioselection of a ratio of >99:1 is achieved in
the hydride transfer step C to D. Here, the key is the carbonyl protonation in C, which is
caused by HCl84 generated in the induction step A to B.
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Scheme 3.17: Asymmetric hydrogenation of β-keto esters catalyzed by an (S)-BINAP-Ru
complex. (a) Reaction scheme. (b) Catalytic cycle.85
The chirality of BINAP is transmitted to other metal coordination sites through the
chelate structure. The δ or λ geometry is highly skewed and determines the chiral
disposition of the P-phenyl rings that play a key role in generating outstanding chirality-
discriminating ability at the reactive coordination sites. Ligation of the ester C-O to the Ru
center stabilizes the transition states (TSs) in the hydride transfer step. In addition, the
oxygen/Ru interaction in transition state is crucial for catalytic activity as well.83
The Figure 3.7 illustrates the chiral environment of an (S)-BINAP–Ru complex.
The second and fourth quadrants are more crowded than the first and third quadrants
because of shielding by the equatorial phenyl groups. The S-directing TS is highly favored
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over the R-generating diastereomer, which suffers from substantial R/P-phenyl repulsive
interaction.
  
Figure 3.7: Diastereomeric transition states of asymmetric hydrogenation of β-keto esters
catalyzed by (S)-BINAP-Ru complexes.85,86
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For the hydrogenation of β-keto esters, the presence of the ester moiety is crucial
for both high reactivity and enantioselectivity. Because of the assistance of the oxygen-Ru
interaction, BINAP can differentiate well between the two stereo-determining
diastereomeric TSs.
Figure 3.8: Empirical rule for predicting the outcome of the asymmetric reduction in the
presence of BINAP-Ru complexes.87
Synthetic Pathway
Ethyl 3-oxoheptanoate (106), available by the general procedure for the preparation
of γ-substituted β-ketoesters, either from carbethoxylation88 of 2-hexanone with
diethylcarbonate in the present of sodium hydride or by aldol-type condensation89 of
pentanal with ethyl diazoacetate, was selected as the starting material for this strategy.
Noyori hydrogenation with chiral ruthenium compound (Ru-107) converted compound
10679,88a to a chiral alcohol 108 in 91% yield, 93% ee as determined by GC (see 3.3.1
Asymmetric Hydrogenation of β-Keto ester). Compound 113 was made according to those
from the synthetic pathway to the 8-hydroxy acid 3b. The subsequent silylation of the
hydroxyl group with tert-butyl-dimethylsilyl chloride (TBSCl) in the presence of imidazole
gave silyl ether 109.90 Reduction91 with diisobutylaluminium hydride (DIBAL-H) yielded
the aldehyde 110 that was converted to the enoate 111 by reaction with the stabilized
Wittig reagent (Ph)3P=CHCO2Me (80).92 Reaction of the enoate with 2.2 equivalents of
DIBAL-H furnished the allylic alcohol 112.93 The allylic alcohol was converted to the
CO2R
'
R
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(S)-BINAP-Ru(II)
O
H2
H2
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hydroxymethylcyclopropane 113 using the combination of diiodomethane, diethylzinc and
the chiral dioxaborolane 67 (Charette method).42 Ethyl 3-oxoheptanoate (106)94 was easily
converted to hydroxymethylcyclopropane 113 in 57% yield over 6 steps. According to the
1H NMR spectrum, this compound was diastereomerically pure (>95%). The sequence
leading to the required building block 113 is shown in Scheme 3.18.
Scheme 3.18: Synthesis of the key building block 113 as an analogue of 61.
However, this analogue was not our main target. Nevertheless, it could be shown
that the general sequence works for aliphatic ketoesters. Further routine steps could convert
the cyclopropyl alcohol 113 to the acid 105.
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A published sequence of reactions was followed to synthesize (S)-2,2′-bis
(diphenylphosphino)-1,1′-binaphthyl (S-BINAP, 107) as a chiral catalyst for hydrogenation
as shown in Scheme 3.19.95 The resolution of (±) 1,1′-bi-2-naphthol (115), prepared in one
step from β-naphthol (114),95c with N-benzylcinchonidinium chloride (116)96 in
acetonitrile, gave (R)- and (S)-binaphthols97 in 44% yield, >99% ee and 49% yield >98%
ee, respectively.95b (S)-Binaphthol was converted with triflic anhydride and pyridine to the
ditriflate 117. This was then subjected to a Ni-catalyzed cross-coupling reaction with four
equivalents of diphenylphosphine (Ph2PH)98, 1,4-diazabicyclo[2.2.2]octane (DABCO) and
a catalytic amount of 1,2-bis(diphenylphosphino)ethane]nickel(II) chloride (NiCl2dpps)
(10%) in DMF at 100 °C, over 2 days, to provide the (S)-BINAP (107) in 60% yield.95a
Using (R)-binaphthol instead, the same sequence and conditions afforded (R)-BINAP.
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Scheme 3.19: Synthesis of chiral ligand 107.
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-ROUTE C
The analog 118 was designed in order to probe the size at the terminus as well as to
see whether hydrophobic effects can influence the activity of jasplakinolide analogues. In
order to connect the aryl ring to the carbon chain we thought of reacting an arylmetal
nucleophile with an epoxide. Hydrolytic kinetic resolution (HKR) catalyzed by chiral
(salen)Co complexes, derived from chiral ligands 119 with cobalt(II)acetate tetrahydrate
(Co(II)(OAc)2.4 H2O),99 has appeared to be a powerful method for the preparation of
enantiomeric pure terminal epoxides.99a (Scheme 3.20) The attractive features of the HKR
include high selectivity factors across a wide range of terminal epoxides. It allows access
to highly enantioenriched (>99% ee) products close to theoretical yields.100 The reaction
protocol also involves a commercially available catalyst, which allows the resolution at
low costs.101
Scheme 3.20: The hydrolytic kinetic resolution catalyzed by chiral (salen)Co complexes.99a
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Introduction of the C8 stereocenter by the HKR technique followed by opening of
the epoxide with the dithiane anion and subsequence hydrolysis of dithiane 120 would
yield the aldeyhyde 63. The remaining sequence leading to target molecule 118 could
proceed as described before.
Scheme 3.21: Retrosynthetic analysis for the synthesis of 8-hydroxy nonenoic acid
derivatives starting with hydrolytic kinetic resolution technique.
Key Reactions and Mechanisms
3.3.2 Hydrolytic Kinetic Resolution
The mechanism of the hydrolytic kinetic resolution (HKR) can be compared with
other asymmetric ring-opening reactions using (salen)-metal complexes. The active
catalyst is the (salen)Co-OH which serves both as a nucleophilic and Lewis acidic
component. Kinetic studies showed that the reaction is second order with regard to the
salen-complex (Scheme 3.22).
CO2HR
TBSO
8
3b derivative
Route A
Procedure
TBSO
CHO
R
R
TBSO
S
S
120
O
R
O
R (±)
HKR
63 derivative
RESULTS AND DISCUSSION 61
Scheme 3.22: The mechanism for hydrolytic kinetic resolution (HKR), considered as a
asymmetric ring-opening reaction.102
Both epoxide enantiomers bind to the Co-OH complex with similar affinity. Thus
the high selectivity in the HKR results not from selective binding to the chiral catalyst, but
from the selective reaction of one of the epoxide complexes.
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Scheme 3.23: A cooperative bimetallic mechanism for hydrolytic kinetic resolution
(HKR). 102
Synthetic Pathway
We examined the utility of complex Co-119 in HKR under standard conditions.99a
In this case, the aromatic (p-methoxy benzyl group) side chain on C8 was selected. Starting
from (±)-121, two possible routes, which differed in the sequence of kinetic resolution and
introduction of the aromatic side chain, were explored. The first approach to epoxide (S)-
123103 was kinetic resolution of epichlorohydrin104 ((±)-121) and subsequent introduction
of the aromatic side chain by nucleophilic substitution with lithium 4-methoxyphenyl
(122). The first approach gave highly enantioenriched (>99% ee) products as determined
by GC. In the second route racemic epoxide was first prepared from epichlorohydrin
followed by HKR. While the chemical yield in the hydrolysis step was satisfactory, the
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enantiomeric purity of the non-hydrolyzed 123 was rather low. The ee-value for the
epoxide was only 19% as measured by GC. The result suggested that the aryl side chain of
123 might cause conflicting steric and electronic effects influencing the regioselectivity in
the epoxide ring opening.99 This could induce low selectivity factors. It was therefore
gratifying to obtain (S)-123 derived from (±)-epichlorohydrin ((±)-121) by introduction of
the aromatic side chain after the HKR.
Scheme 3.24: Two possibilities for the synthesis of epoxide (S)-123 using HKR.
The next step was treatment of 2-tert-(butyldimethlsilyl)-1,3-dithiane105 (124) with
t-BuLi, followed by addition of the terminal epoxide (S)-123 to generate the intermediate
alkoxy dithiane 125. Brook rearrangement was triggered by addition of HMPA. After
quenching of the reaction with NH4Cl the silyl ether 126 was obtained in 75% yield.106
Dithiane 126 was converted to aldehyde107 127 by treatment with methyl iodide-calcium
carbonate in aqueous acetonitrile.108 Since aldehyde 127 was considered as an analogue of
aldehyde 79, the remaining steps to the desired acid were subsequently patterned according
to those of route A. Thus, compound 127 was converted to the enoate63 128 by reaction
with the stabilized Wittig reagent (Ph)3P=CHCO2Me (80). Reaction of the enoate 128 with
2.2 equivalents of DIBAL-H furnished the allylic alcohol 12965 which was converted to the
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hydroxymethylcyclopropane 130 using a combination of diiodomethane, diethylzinc and
the chiral dioxaborolane 67 (Charette method).42 The sequence leading to the required
hydroxymethylcyclopropane 130 is shown in Scheme 3.25.
Scheme 3.25: Synthesis of the hydroxymethylcyclopropane 130.
For the conversion of the primary alcohol 130 to the corresponding iodide 133 we
initially followed the pathway via the mesylate 132. However treatment of the alcohol 130
with mesyl chloride and triethylamine provided only the mesyl alcohol 131 with the silyl
ether being cleaved. Therefore iodide 133 was obtained by treatment of alcohol 130 with
triphenyl phosphite and methyl iodide.66 After a couple of trials, iodide 133 was obtained
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in fair yield.109 The reductive ring opening67 of the cyclopropane ring with n-butyllithium
in THF between -78 and -30 °C provided the alkene 134 in 50% isolated yield. According
to the 13C NMR spectrum, this compound is diastereomerically pure (>97%).
Scheme 3.26: Synthesis of to the key building block 134.
If one compares the above result with those from the natural product (route A) it
can be seen as moderately efficient. Even more surprising results were observed from the
cross coupling metathesis110 of the terminal alkene 134 with methyl methacrylate (92)
because only black oil was obtained. It was not possible to purify the resulting product. To
circumvent the problem, other alternatives to reach enoate 135 were examined.
Unfortunately, all attempts at the synthesis of the aldehyde 136 or the diol 137 by
oxidizing the double bond with ozone,70 AD mix111 or potassium osmate dihydrate
(K2OsO4 .2H2O)112 also failed.
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Scheme 3.27: Attempts for the synthesis of the enoate 135.
We thought that unwanted cleavage of the TBS-group during the metathesis and
oxidation reactions was to blame for the failure. Therefore the TBS-group was replaced by
the TBDPS-group. The desired allyl compound 139 with a new protecting group was then
prepared accordingly. After removal of the TBS-protecting group with TBAF to give free
secondary alcohol 138,65a the compound 139 was obtained by subsequent silylation of the
free hydroxy group of 138 with t-butyl-diphenylsilyl chloride (TBDPSCl) in the presence
of imidazole.90 The prepared alkene 139 was then coupled with methyl-2-methylacrylate
(92) by the general procedure110 with various conditions for the cross coupling metathesis.
Unfortunately, the result was disappointing again. No desired product was observed. The
next attempt was the oxidation of the double bond either with ozone70 or potassium osmate
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dihydrate (K2OsO4 .2H2O)112 to the aldehyde 141 and the diol 142. These attempts were
also unsuccessful. The attempts to prepare enoate 140 are shown in Scheme 3.28.
Scheme 3.28: Attempts of the synthesis of the enoate 140.
It seems that the presence of the electron rich aromatic ring is the reason for the
failure of the alkene 60 modification. In order to obtain compound 118 other strategies
would be required that do not take the path through alkene 134. However, at this point we
concentrated our effort on developing another route to the natural nonenoic acid 3b.
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-ROUTE D
Enantioselective catalytic transformations that involve C-C bond formation are
rather rare as compared to functionalizing conversions of a given carbon skeleton.113
Among the best studied reactions of these types are nucleophillic additions to carbonyl
compounds catalyzed by modified Lewis acids as electron-withdrawing chiral ligands.113a,
114 This is especially true for the reaction of diethyl zinc with aldehydes.113a,115
We planned to use this reaction for the introduction of the chiral center at C8. The
aldehyde substrate was chosen in such a way to allow creation of the stereocenter at C6 by
a diastereoselective methylation on a lactone template. From lactone 34 the strategy of
White could be used.26 Consequently, the key element in this synthesis is the preparation of
analogues of 32.116
Scheme 3.29: Retrosynthetic analysis for the synthesis of 8-hydroxy nonenoic acid
derivatives by starting with a symmetric alkylation of an aldehyde.
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Key Reactions and Mechanisms
The catalytic asymmetric addition of alkyl groups to aldehydes is an important
reaction for the enantioselective synthesis of secondary alcohols. The addition of
organometallic reagents to carbonyl groups has proven to be the one of the most successful
reactions in this regard. For instance the addition of dialkylzinc reagents to aldehydes in
the presence of chiral Lewis acid catalysts can result in excellent enantioselectivities.115
Among some successful catalysts in these reactions are titanium complexes which employ
chiral amino alcohol,117 diol118 or bis(sulfonamide)119 based ligand systems (Scheme 3.30).
Scheme 3.30: Alkylation of aldehydes in the presence of chiral Lewis acid catalysts.
Although a wide variety of dialkylzinc reagents and aldehydes have been
employed, the mechanism of this process has not been adequately explored. Two possible
transition states to explain the asymmetric addition reaction have been proposed (Figure
3.9).117a
Figure 3.9: Possible transition states for the asymmetric addition reaction.
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3.3.3 Asymmetric Alkylation catalyzed by Bis(sulfonamide) Ligands
Bis(sulfonamide) ligands form efficient and highly enantioselective catalysts for a
number of reactions.119b These ligands are highly effective in the asymmetric amination of
N-acyloxazolidinones with magnesium catalysts,120 asymmetric cyclopropanation of allylic
alcohols with zinc catalysts,121 and the asymmetric Diels-Alder reaction with aluminum
Lewis acids.122 The Lewis acidic magnesium bis-(sulfonamido) complex can potentially
coordinate the sulfonyl oxygens, and evidence exists for this interaction in related systems.
123 Bis(sulfonamide) ligands gave poor enantioselectivities when used with dialkylzinc
reagents alone. However when titanium tetraisopropoxide was added, the resulting
catalysts proved to be highly enantioselective.119 The further scope of this process was
delineated by employing a variety of aldehydes and functionalized dialkylzinc reagents to
provide elaborate secondary alcohols with excellent enantioselectivity.119,124
It is conceivable that the bis(sulfonamide) reacts first with R2Zn and then is
transmetalated to titanium.125 It is also possible that an equilibrium between the titanium
complex and the bis(sulfonamide) species as shown in Scheme 3.31 exists.126 The
equilibrium is driven to the right by reaction of the dialkylzinc reagent with liberated 2-
propanol.
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Scheme 3.31: The possible equilibrium between disulfonamide and titanium complex.117a
It could be possible that the oxygen atoms of the sulfonamide group are involved in
the complexation of the titanium. This would require a C2-symmetric conformation as
indicated in Figure 3.10.117a,119,124g,127 However, it is not clear whether the titanium
complex is a monomer119b,124g or dimer128.
Figure 3.10: Proposed transition state for exchange of chiral alkoxides.117a
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3.3.4 Asymmetric Alkylation catalyzed by TADDOLates
TADDOL contain two adjacent diarylhydroxymethyl groups in a trans relationship
on a 1,3-dioxolane ring. The TADDOL family of ligands has a large number of analogues
with different aromatic substituents and acetal moieties.129 They can be prepared from
acetals or ketals of tartrate esters by reaction of the latter with aromatic Grignard reagents.
TADDOL ligands have been used very successfully in many areas of asymmetric synthesis
as extraordinarily versatile chiral ligands for some metals such as titanium or
aluminium.129,130
The free rotation of the diphenylmethanol moiety of the unbound ligand is
constrained upon metallacycle formation to give a trans-fused bicyclo[5.3.0]decane ring
system.129,131 This interaction can limit the degrees of rotational freedom within the metal-
ligand framework. The stereocenters of the dioxolane are too far removed from the metal
center to have a stereodiscriminating effect. Nonetheless they exert a powerful
conformational preference on the adjacent metallacycle, effectively directing the
diastereomeric aromatic substituents to adopt pseudoequatorial and pseudoaxial positions.
As a result, the extending and rigidifying of the asymmetric environment of the stereogenic
centers is projected forward to the metal center. The asymmetrically disposed aryl groups
define the chiral environment of the catalyst and the preferential orientation of binding of a
substrate, as shown in Figure 3.11.132
TADDOL
O
O
OH
OH
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Figure 3.11: Effect of TADDOLate aryl groups on the binding of a substrate aldehyde.
(The dioxolane moiety has been omitted for clarity.)132
Synthetic Pathway
This part of the study began with the enantioselective alkylation of the
commercially available ethyl (E)-4-oxobutenoate (144) with some selected chiral catalysts
and the R2Zn-Ti(O-i-Pr)4 system. The chiral titanium compounds can be derived from
chiral ligands with titanium(IV) isopropoxide (Ti(O-i-Pr)4).
Scheme 3.32: Synthesis of the secondary alcohol 149 by enantioselective alkylation of
commercially available aldehyde 144.
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The preparation of (R,R)-1,2-bis(trifluoromethanesulfonamide)cyclohexane (145)
133 started from (R,R)-1,2-diaminocyclohexane (151)134, which was generated from (R,R)-
1,2-diaminocyclohexane mono-(+)-tartarate salt (150) by treatment with 4 equivalents of
KOH. The chiral free diamine was then condensed with trifluoromethanesulfonyl chloride
to give the bis(sulfonamide) ligand119 145 in 60% yield. Treatment of the chiral free
diamine 151 with heptadecafluorooctanesulfonyl chloride under the same conditions gave
bis(sulfonamide) ligand 146 (Scheme 3.33).
Scheme 3.33: Synthesis of chiral bis(sulfonamide) ligands 145 and 146.
The chiral disulfonamide ligand 145 was initially selected for this study. This
asymmetric alkylation of the aldehyde 144 should give the secondary alcohol 149 in high
chemical yields and excellent enantiomeric purity.119,133,135 As a test reaction the alkylation
of benzaldehyde with diethylzinc in the presence of ligand 145 was performed. As reported
in literature117,119,125,127,135,136 an excellent result was obtained. The enantiomeric excess
value (ee) was measured by HPLC as shown in Figure 3.12.
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Figure 3.12: HPLC-Diagram: (a) rac-1-phenylpropanol. (b) (1S)-1-phenylpropanol.a
Note: a) device: HP 1100 series; column: chiracel OD-RH, 150 x 4.6 mm; eluent: NaCl
solution (5 mM) / acetonitrile, gradient: 0-10-18-20-25 min with 20-80-80-99-
99% acetonitrile, flow: 0.1 mL/min.
However, with the aldehyde 144 only a very low ee of 6% was obtained as
determined by GC. The product was a nearly equal racemic mixture of two allylic alcohols
(S)-149 and (R)-149, in a ratio of enanitomers, in a ratio of 53:47. Nevertheless, the
alkylation of 144 with diethylzinc in the presence of ligand 145 has never been reported.
76 RESULTS AND DISCUSSION
Scheme 3.34: Ethylation by chiral disulfonamide catalyst Ti-145.
We thought that increasing the electron-withdrawing group on the amino functions
might lead to a better catalyst.119 Therefore we targeted ligand 146. However this ligand
turned out to be too labile and unstable.
Another ligand that has been used for this study is TADDOL. Diethyl L-tartarate
(84) was converted into the cyclic ketal ester 152 by condensation with 2,2-
dimethoxypropane in the presence of a catalytic amount of toluenesulfonic acid.137 The
TADDOLs were obtained from the tartrate ester acetal precursor 152 and the
corresponding aryl Grignard reagents. Here, the TADDOLs (-Ph)113a,118d,131b,138 147 and (-
Np)113a,118d,131b,138a-c 148 were prepared as shown in Scheme 3.35.
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Scheme 3.35: Synthesis of chiral TADDOL ligands 147 and 148.
The results obtained in the asymmetric alkylation118d of aldehyde 144 with the
different Ti-TADDOLates are summarized in Table 3.6. (see 3.3.4 Asymmetric Alkylation
catalyzed by TADDOLates)
Table 3.6: Studies on ethylation of aldehyde 144 in the presence of Ti-TADDOLs.
Equiv. of TADDOL [%]
yield(-Ph)
147
(-Np)
148 149 153 149 + 153
ee of
149
      0.05 - 51 11 62 87
      0.1 - 51 11 62 93
      0.2 - 47 11 58 95
-     0.01 57 11 68 77
- 0.1 63 11 74 98
- 0.2 64 11 75 98
Note: a) The enantiomeric excess values (ee) were measured by GC.
The results listed in Table 3.6 reveal some informative data. Although iso-propyl
hexenoate 153139 was obtained as the side product from the synthesis of chiral secondary
alcohol 149139,140, the subsequent steps allowed the preparation of the key building block
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156 from both products. Thus, both were employed for the next procedure without any
separation. Under the above conditions products 149 and 153 were generally obtained in
good yield (58-75%) and high enantiomeric excess (77-98%). Among the two ligands,
TADDOL (-Np) 148 showed slightly better results. This catalyst was therefore selected for
further investigation and the result of the alkylation under the optimized conditions is
shown in Scheme 3.36. The enantiomeric excess values (ee) of 154140,141 was measured by
GC-MS.
Scheme 3.36: Alkylation of aldehyde 144 in the presence of Ti-148.
The mixture of allylic alcohols 149 and 153 was transformed smoothly to the
hydroxyesters 154116,142 and 155143 by hydrogenation of the double bond.141f,144 Subsequent
heating of the hydroxy esters under acidic conditions led to the lactone 156.116,145
Since the methyl derivative of lactone 156 was used in the White synthesis26 one
could use a similar strategy to convert 156 to the analog 143. Due to time constraints this
was not further pursued. The sequence leading to the key building block 156 is shown in
Scheme 3.37.
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Scheme 3.37: Synthesis of the key building block 156.
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4 CONCLUSION
The core of this dissertation was the development of an economically feasible
asymmetric synthesis of the protected 8-hydroxy-2,4,6-trimethyl-4-nonenoic acid (3b).
This would correspond to a formal total synthesis of jasplakinolide. This moiety, related to
that found in the geodiamolide family of natural products, consists of 12 carbons with three
chiral centers and one geometric configuration as a double bond in the backbone.
To effect the synthesis for the natural derivative, a methodology of route A was
investigated. To achieve chain extension toward the ω-hydroxy acid 3b, acetoacetate 64
was selected as the starting material. While the route was still not optimal, it provided the
acid in 15 steps which an overall yield of 20%. This allowed the laboratory synthesis of 2 g
of this material. Key steps of this synthesis included: yeast reduction, the Charette method
for diastereoselective cyclopropanation, a cross alkene metathesis reaction, and finally an
Evans alkylation resulting in the 8-hydroxy acid derivative 3b. The attempts to attain
higher yields of hydroxy acid 3b over less steps via the cross coupling metathesis of olefin
60 with various 2-methyl-olefins (99-104) containing the remainder of the basic skeleton,
were unsuccessful. However, we found that only methyl methacrylate (92) was suitable for
the cross-metathesis.
In a complementary study, three more methods (routes B-D) for the synthesis of
derivatives of the 8-hydroxy acid were investigated. The fundamental steps in these
strategies are: a Noyori asymmetric reduction, hydrolytic kinetic resolution (HKR), and
enantioselective alkylation of an aldehyde catalyzed by TADDOL derivatives. In route B,
the yeast reduction of acetoacetate (64, routes A) was replaced by the Noyori reduction of
the β-ketoester. In this way ethyl 3-oxoheptanoate (106) could be easily converted to
building block 113 in good yield. Route C is based on the hydrolytic kinetic resolution
(HKR), catalyzed by a chiral (salen)Co complex of a racemic epoxide. The complex was
derived from the chiral ligand 119 with cobalt(II)acetate tetrahydrate (Co(II)(OAc)2.4
H2O). This route started from (±)-epichlorohydrin (121) by the HKR technique. A
subsequent alkylation of the dithianyl anion with epichlorohydrin, followed by Brook
rearrangement produced compound 120. Hydrolysis of the dithiane group then resulted in
the aldehyde 127. The further steps forward the target molecule 118 were performed
similar to the procedure from route A. Route D is the study of the enantioselective
alkylation of ethyl (E)-4-oxobutenoate (144) with some chiral catalysts (145, 147 and 148)
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and the R2Zn-Ti(O-i-Pr)4 system. In this part of the study, the key building block, lactone
156 was obtained in a very efficient way. These three additional routes were supposed to
provide a wide range of acid-like molecules in good quality and quantity. The synthetic
analysis of the 8-hydroxy acid and acid-like molecules of jasplakinolide, as discussed, is
shown in Figure 4.1.
Figure 4.1: The synthetic analysis of the 8-hydroxy aicd and acid-like molecules of
jasplakinolide.
From this study, the chemistry performed allows the synthesis of the important
bioactive marine cyclodepsipeptide jasplakinolide from commercially available and
inexpensive starting materials. Four approaches to the polypropionate-like fragment were
developed. The product was planned to be used for the construction of novel macrocyclic
systems. The chemistry developed should be applicable to the synthesis of a wide range of
novel peptide-polypropionate macrocycles. In summery, it can be said that acid 3 is a
tough synthetic target and an interesting lead compound for conformational design.
Lessons learnt from this study will direct the design of simpler analogs. This will be the
subject of future investigations.
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cyclopropanation (Charette method) and ring opening
a) Wittig reaction
b) cross coupling metathesis by Grubbs Cat. II
Evans alkylation
a) Baker's yeast reduction of acetoacetate 
b) Noyori hydrogenation of β-ketoester
c) hydrolytic kinetic resolution of (±)-epichlorohydrin 
d) enantioselective alkylation by some chiral ligands
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5.1 General Remarks
5.1.1 Chemicals and Working Technique
The chemicals were purchased from the firms Acros, Aldrich, Fluka, Lancaster,
Avocado and Merck. They were used directly without further purification if nothing else
was mentioned. All solvents were purified prior to use by standard methodology except for
those which were reagent grades. The applied petrol ether fraction had a b.p. of 40-60 °C.
Anhydrous solvents were obtained as follows: THF, diethyl ether and toluene by
distillation from sodium and benzophenone; dichloromethane and chloroform by
distillation from calcium hydride; dimethylformamide and dimethylsulfoxide by vacuum
distillation from calcium hydride; acetone by distillation from phosphor(V)-oxide.
Absolute triethylamine and pyridine were distilled from calcium hydride prior to use. 1,2-
dimethoxyethane was distilled prior to use. Unless mentioned, all the reactions were
carried out under an nitrogen atmosphere and the glass material was pre-dried by flame
drying under high vacuum (oil pump RV 5, Edwards). All the chemicals, which were air or
water sensitive, were stored under inert atmosphere. Compounds which are not described
in the experimental part, were prepared according to the literature.
5.1.2 NMR-Spectroscopy
The spectra were measured on a Bruker Avance 400 spectrometer which operated
at 400 MHz for 1H and 100 MHz for 13C nuclei, respectively. 1H and 13C NMR spectra
were performed in deuterated solvent and chemical shifts were assigned by comparison
with the residual proton and carbon resonance of the solvent and tetramethylsilane (TMS)
as an internal reference (δ = 0). Data are reported as follows: chemical shift (multiplicity: s
= singlet, d = doublet, t = triplet, m = multiplet, br = broadened; J = coupling constant
(Hz), integration, peak assignment).
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5.1.3 Mass Spectrometry
Mass spectra were recorded on a Finnigan Triple-Stage-Quadrupol Spectrometer
(TSQ-70) from Finnigan-Mat. High-resolution mass spectra were measured on a modified
AMD Intectra MAT 711 A from the same company. The used mass spectrometric
ionization methods were electron-impact (EI), fast-atom bombardment (FAB) or field-
desorption (FD). FT-ICR-mass spectrometry and HR-FT-ICR mass spectra were measured
on an APEX 2 spectrometer from Bruker Daltonic with electrospray ionization method
(ESI). Some of the mass spectra were also measured on an Agilent 1100 series LC/MSD
(API-ES). Significant fragments are reported as follows: m/z (relative intensity).
5.1.4 Infrared Spectroscopy
The FT-IR spectra were recorded on a Fourier Transformed Infrared
Spectrophotometer model Jasco FT/IR-430 from the company Jacso. Solid samples were
pulverized with potassium bromide and percent reflection (R%) was measured. The
percent transmittance (T%) of liquid or oily substances was measured in film between
potassium bromide tablets. Absorption band frequencies are reported in cm-1.
5.1.5 Polarimetry
Optical rotations were measured on a JASCO Polarimeter P-1020. They are
reported as follows: [α]temperatureD (concentration, solvent). The unit of c is g/100 mL. As a
solvent was used anhydrous CH2Cl2 or CHCl3. For the measurement was used the sodium
D line = 589 nm.
5.1.6 Melting Points
Melting points were determined with a Büchi Melting Point B-540 apparatus and
were not corrected.
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5.1.7 Chromatographic Methods
Flash column chromatography was performed using flash silica gel (40-63 µm,
230-400 mesh ASTM) from Macherey-Nagel.
Gaschromatography was performed on a CHROMPACK CP 9000 using a flame
ionization detector, and carrier gas H2. For GC-MS coupled chromatography, GC-system
from Series 6890 with an Injector Series 7683 and MS-detector Series 5973 from Hewlett
Packard was used, with EI method, and carrier gas He. Analytical HPLC was performed on
a Hewlett Packard HP 1100 system.
Analytical thin-layer chromatography (TLC) was performed on aluminum sheets
pre-coated with silica gel 60 F254 plates (Merck) or Polygram Sil G/UV254 (Macherey-
Nagel). The compounds were visualized by UV254 light and the chromatography plates
were developed with an aqueous solution of molybdophosphorous acid or aqueous solution
of potassium permanganate (heating on a hot-plate). For preparation of the molybdate
solution were used 20 g ammonium molybdate [(NH4)6Mo7O24 x 4H2O] and 0.4 g Cer
(SO4)2 x 4H2O dissolved in 400 mL 10% H2SO4. The potassium permanganate solution
was prepared from 2.5 g KMnO4 and 12.5 g Na2CO3 in 250 mL H2O.
5.2 Synthesis of the 8-Hydroxy Acid of Jasplakinolide
(2S,4E,6R,8S)-8-{[tert-Butyl(dimethyl)silyl]oxy}-2,4,6-trimethylnon-4-enoic acid (3b)
 A cooled (0 °C) solution of the oxazolidinone 96 (73 mg, 0.15 mmol) in THF (2.5
mL) was treated with H2O2 (35% by weight, 68 µL, 0.60 mmol), then with a solution of
LiOH * H2O (13 mg, 0.30 mmol) in H2O (1 mL). The solution was stirred at 0 °C for 1.5 h.
After TLC indicated completion of the hydrolysis, a mixture of saturated Na2SO3 (2 mL)
and saturated NaHCO3 (2 mL) was added at 0 °C. The mixture was partially concentrated
and then diluted with H2O (2 mL). The aqueous solution was extracted with CH2Cl2 (3 x 5
mL). The combined organic extracts were dried (MgSO4), filtered and concentrated. The
crude product was purified by flash chromatography (petroleum ether/Et2O, 6:1) to afford
TBSO
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the acid 3b as a colorless oil (49 mg, 100%). TLC (petroleum ether/ethyl acetate, 6:1): Rf =
0.57; [α]D22 -9.0 (c 0.23, CH2Cl2) {Ref.17 [α]D25 -9.2 (c 1.1, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.03 (s, 6H, SiCH3), 0.87 (s, 3H, CH3), 0.87 (s, 9H, SiC
(CH3)3), 1.08 (d, J = 6.3 Hz, 3H, CH3), 1.10 (d, J = 7.3 Hz, 3H, CH3), 1.25-1.31 (m, 1H, H-
7), 1.39-1.45 (m, 1H, H-7), 1.59 (s, 3H, CH3), 1.98-2.04 (m, 1H, H-3), 2.35-2.41 (m, 1H,
H-3), 2.38-2.46 (m, 1H, H-6), 2.56-2.65 (m, 1H, H-2), 3.70-3.78 (m, 1H, H-8), 4.96 (d, J =
9.5 Hz, 1H, H-5), 11.43 (s, br, 1H, COOH).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.4 (SiCH3), 15.6 (C-4a), 16.1 (C-2a), 18.3 (SiC
(CH3)3), 20.9 (C-6a), 23.6 (C-9), 25.9 (SiC(CH3)3), 29.1 (C-6), 37.8 (C-2), 43.8 (C-3), 47.5
(C-7), 66.7 (C-8), 129.9 (C-5), 134.3 (C-4), 183.0 (C-1).
IR (neat): ν~  = 2957, 2929, 2857, 1709, 1255 cm-1.
(2R,4S)-4-{[tert-Butyl(dimethyl)silyl]oxy}-2-methylpentanal (20)
The ozonide 89 was reduced to the aldehyde 20 by the addition of of dimethyl
sulfide (60 mL, 2 mL/mmol). The solution was allowed to warm to room temperature and
stirred for 7 days, then washed with H2O (2 x 50 mL) and brine (2 x 50 mL), respectively.
The organic layer was dried (MgSO4), filtered and concentrated. The residue was purified
by flash chromatography (petroleum ether/Et2O, 15:1) to afford aldehyde 20 as a colorless
oil (6.71 g, 97%, over 2 steps from alkene 80). TLC (petroleum ether/ethyl acetate, 16:1):
Rf = 0.47; [α]D24 +6.20 (c 0.89, CHCl3) {Ref.28b [α]D25 +23.2 (c 0.06, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.05 (s, 6H, SiCH3), 0.87 (s, 9H,
SiC(CH3)3), 1.09 (d, J = 6.0 Hz, 3H, CH3), 1.16 (d, J = 6.1 Hz, 3H, H-5), 1.47-1.54 (m, 1H,
H-3), 1.80-1.87 (m, 1H, H-3), 2.47-2.57 (m, 1H, H-4), 3.83-3.96 (m, 1H, H-4), 9.61 (s, 1H,
H-1).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.1 (SiCH3), 13.4 (CH3), 18.0 (SiC(CH3)3), 24.3
(C-5), 25.8 (SiC(CH3)3), 40.4 (C-3), 43.5 (C-2), 66.1 (C-4), 205.2 (C-1).
IR (neat): ν~  = 2957, 2930, 2858, 1728, 1255.
TBSO
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(2E,4R,6S)-6-{[tert-Butyl(dimethyl)silyl]oxy}-1-iodo-2,4-dimethylhept-2-ene (59)
A solution of the crude mesylate 94 (274 mg, 0.78 mmol) in dry acetone (5 mL)
was treated with sodium iodide (1.05 g, 7.0 mmol) at 0 °C. After being stirred for 3 h at
room temperature, the mixture was diluted with petroleum ether (10 mL) and washed with
H2O (5 mL). The aqueous phase was extracted with Et2O (3 x 5 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered and concentrated. The
crude product was purified by short flash chromatography (petroleum ether/Et2O, 1:1) to
yield the iodide 59 as a pale yellow oil (292 mg, 94% from 93). TLC (petroleum
ether/ethyl acetate, 100:1): Rf = 0.40.
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.88 (s, 9H, SiC(CH3)3), 0.90 (d, J =
4.0 Hz, 3H, H-4a), 1.10 (d, J = 6.1 Hz, 3H, H-7), 1.26-1.33 (m, 1H, H-5), 1.39-1.46 (m,
1H, H-5), 1.76 (s, 3H, H-2a), 2.37-2.46 (m, 1H, H-4), 3.71-3.77 (m, 1H, H-6), 3.92 (s, 2H,
H-1), 5.44 (d, J = 9.6 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.3 (SiCH3), 15.5 (CH3C=CH), 17.0 (C-1), 18.1
(SiC(CH3)3), 19.8 (CH3CH), 23.8 (C-7), 25.9 (SiC(CH3)3), 29.6 (C-4), 47.0 (C-5), 66.3 (C-
6), 131.3 (C-2), 136.2. (C-3).
IR (neat): ν~ = 2957, 2928, 2857, 1361, 1256 cm-1.
HRMS: calcd. for C15H31OISiNa 405.10867, found 405.10812.
(3R,5S)-5-[tert-Butyl(dimethyl)silyl]oxy-3-methylhex-1-ene (60)
A solution of the iodide 83 (15.6 g, 44.0 mmol) in dry Et2O (250 mL) containing 4
Å molecular sieves (7.7 g) and TMEDA (13.2 mL, 88 mmol) was treated with n-BuLi (2.5
M in hexane, 35.2 mL, 88 mmol) at -78 °C. The resulting mixture was stirred at –78 °C for
1 h, then the temperature was raised to –30 °C over 2 h. The reaction was quenched with
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H2O (100 mL). The layers were separated and the aqueous layer was extracted with Et2O
(3 x 75 mL). The combined organic layers were successively washed with 10% HCl (100
mL), saturated NaHCO3 solution (100 mL), H2O and brine, respectively. The organic layer
was dried (MgSO4), filtered, and concentrated. The crude product was purified by flash
chromatography (petroleum ether) to give the alkene 60 as a colorless oil (7.33 g, 73%
yield, > 98% de). TLC (petroleum ether): Rf = 0.44; [α]D26 +3.91 (c 0.98, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.87 (s, 9H, SiC(CH3)3), 0.98 (d, J =
6.7 Hz, 3H, CH3), 1.12 (d, J = 6.0 Hz, 3H, H-6), 1.24-1.29 (m, 1H, H-4), 1.49-1.56 (m, 1H,
H-4), 2.19-2.26 (m, 1H, H-3), 3.78-3.85 (m, 1H, H-5), 4.90 (d, J = 10.3 Hz, 1H, H-1), 4.93
(d, J = 17.2 Hz, 1H, H-1), 5.65-5.74 (m, 1H, H-2).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.3 (SiCH3), 18.1 (SiC(CH3)3), 20.1 (CH3), 23.7
(C-6), 25.9 (SiC(CH3)3), 34.4 (C-3), 46.7 (C-4), 66.5 (C-5), 112.2 (C-1), 144.8 (C-2).
IR (neat): ν~  = 2957, 2927, 1463 cm-1.
HRMS: calcd. for C13H28O2Si [M - 1]+ 227.183116, found 227.183745.
[(1S,2R)-2-((2S)-2-{[tert-Butyl(dimethyl)silyl]oxy}propyl)cyclopropyl]methanol (61)
To a solution of CH2Cl2 (300 mL) and 1,2-dimethoxyethane (DME) (10.4 mL, 100
mmol) was added a solution of diethylzinc (1.0 M in hexane, 100 mL, 100 mmol) at -10 °C
followed by the dropwise addition of CH2I2 (16.1 mL, 200 mmol) over 15-20 min while
maintaining the internal temperature between -8 and -12 °C. After complete addition, the
resulting clear solution was stirred for 10 min at –10 °C before a solution of dioxaborolane
ligand 67 (16.21 g, 60 mmol) in CH2Cl2 (50 mL, 1.2 M) was added via cannula over a 15-
20 min period while maintaining the internal temperature below –5 °C. This was followed
by the dropwise addition of alcohol 81 (11.5 g, 50.0 mmol), dissolved in CH2Cl2 (50 mL)
while maintaining the internal temperature below -5 °C. After being stirred for 0.5 h at -10
°C, the mixture was allowed to reach room temperature and stirred for 15 h. The reaction
was quenched with saturated NH4Cl solution (50 mL) and 10% of HCl (200 mL) and the
mixture was extracted with Et2O (3 x 100 mL). The combined organic layers were added to
a mixture of 2 N NaOH (300 mL) and H2O2 (30%, 50 mL). The biphasic solution was
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stirred for 5 min and then the layers were separated. The organic phase was washed with
10% of HCl (250 mL), Na2SO3 (250 mL), NaHCO3 (250 mL), and brine (250 mL). After
drying (MgSO4), filtration and concentration of the organic layer under reduced pressure,
the crude product was purified by flash chromatography (petroleum ether/Et2O, 5:1) to
afford 61 as a colorless oil (11.73 g, 96%, the diastereomeric ratio was determined in the
next step). TLC (petroleum ether/ethyl acetate, 4:1): Rf = 0.47; [α]D26 +22.2 (c 0.97,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.04, 0.05 (2 s, 3H each, SiCH3), 0.29-0.39 (m, 2H,
cyclopropane CH2), 0.63-0.72 (m, 1H, H-2′), 0.83-0.90 (m, 2H, H-1′), 0.88 (s, 9H, SiC
(CH3)3), 1.12-1.19 (m, 1H, H-1′′), 1.15 (d, J = 6.1 Hz, 3H, CH3), 1.53-1.60 (m, 1H, H-1′′),
3.37-3.52 (m, 2H, CH2OH), 3.85 (q, J = 6.1 Hz, 1H, CHOR).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.5 (SiCH3), 9.9 (cyclopropane CH2), 13.8
(cyclopropane C-2′), 18.1 (SiC(CH3)3), 21.1 (cyclopropane C-1′), 23.6 (CH3), 25.9 (SiC
(CH3)3), 43.5 (CH2), 67.1 (CHOR), 68.7 (CH2OH).
IR (neat): ν~  = 3348 (br), 2956, 2929, 2857, 1255 cm-1.
HRMS: calcd. for C13H28O2SiNa 267.17508, found 267.17513.
Methyl (2E,5S)-5-{[tert-butyl(dimethyl)silyl]oxy}-2-hexenoate (62)
A mixture of the aldehyde 79 (51 mg, 0.25 mmol) and carbomethoxymethylene
triphenylphosphorane (80) (92 mg, 0.28 mmol) in benzene (2 mL) was refluxed overnight
(80 °C, 16 h). The resulting precipitate was removed by filtration and washed with cold (0
°C) Et2O. The filtrate was concentrated and the residue purified by chromatography
(petroleum ether/Et2O, 15:1) to afford the enoate 62 as a colorless oil (67 mg, 97%,
trans/cis, 33:1 as determined by relative peak heights in the 1H NMR spectrum). The
reaction also was performed 17 g scale of the aldehyde 79 (17.3 g, 86 mmol) with
carbomethoxymethylene triphenylphosphorane (80) (34.4 g, 103 mmol) in benzene (300
mL). In this case afforded 18.8 g (80%) of enoate 62. TLC (petroleum ether/ethyl acetate,
16:1): Rf = 0.45; [α]D26 +7.78 (c 0.98, CHCl3) {Ref.63c [α]D18 +8.94 (c 1.01, CHCl3)}.
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1H NMR (400 MHz, CDCl3): δ = 0.01, 0.02 (2 s, 3H each, SiCH3), 0.85 (s, 9H, SiC(CH3)
3), 1.13 (d, J = 6.1 Hz, 3H, H-6), 2.27-2.31 (m, 2H, H-4), 3.70 (s, 3H, OCH3), 3.86-3.94
(m, 1H, H-5), 5.81 (d, J = 15.7 Hz, 1H, H-2), 6.93 (dt, J = 15.7, 7.7 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -4.9, -4.6 (SiCH3), 18.0 (SiC(CH3)3), 23.7 (C-6), 25.8
(SiC(CH3)3), 42.4 (C-4), 51.3 (CH3), 67.6 (C-5), 122.8 (C-2), 146.3 (C-3), 166.8 (C-1).
IR (neat): ν~  = 2954 , 2930, 1729, 1258 cm-1.
Ethyl (3R)-3-hydroxybutanoate (63)36
A solution of 180 g of sucrose (commercially available sugar) in H2O (950 mL)
was stirred at room temperature for 5 min, until the solution became homogeneous.
Thereafter 120 g of baker’s yeast was added to the solution. The mixture was stirred for 1 h
at 30 °C, ethyl acetoacetate (64, 12.0 g, 92 mmol) was added, and the suspension was
stirred for another 24 h at room temperature. A warm (ca. 40 °C) solution of 120 g of
sucrose in H2O (60 mL) was then added, followed 1 h later by additional ethyl acetoacetate
(64) (12.0 g, 92 mmol). Stirring was continued for 72 h at room temperature, reaction was
complete by TLC. Then celite (48 g) was added and the resulting heterogeneous solution
was stirred for 0.5 h and then filtered. The filtrate was washed with H2O (120 mL). It was
saturated with NaCl and extracted with Et2O (5 x 150 mL). The combined organic phase
was dried (MgSO4), filtered, and concentrated. The crude product was purified by
distillation at 65-75 °C (15-20 mbar) to give the hydroxy ester 63 as a colorless oil (17.8 g,
135 mmol, 73% yield, 89% ee). TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.55; [α]25D
+33.3 (c 1.14, CH2Cl2) {Ref.36 [α]D25 +37.2 (c 1.3, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 1.15 (d, J = 6.3 Hz, 3H, H-4), 1.19 (t, J = 7.2 Hz, 3H,
CH3), 2.36 (dd, J = 14.5, 5.4 Hz, 1H, H-2), 2.38 (dd, J = 14.5, 7.5 Hz, 1H, H-2), 3.33 (s,
1H, OH), 4.04-4.13 (m, 2H, CH2), 4.07-4.15 (m, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = 14.5 (CH3), 22.8 (C-4), 43.3 (C-2), 61.0 (CH2), 64.6 (C-
3), 173.2 (C-1).
IR (neat): ν~  = 3446 (br), 2978, 1735, 1375, 1254 cm-1.
OH
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Ethyl (3S)-3-{[tert-butyl(dimethyl)silyl]oxy}butanoate (78)
To a stirred solution of alcohol 63 (38.3 g, 0.29 mol) in CH2Cl2 (500 mL) was
added imidazole (39.5 g, 0.58 mol) at 0 °C and the mixture stirred for 5 min resulting in a
homogeneous solution. Subsequently, tert-butyldimethylsilyl chloride (52.6 g, 0.348 mol)
was added and the whole mixture stirred for 0.5 h at 0 °C and then at room temperature for
21 h. The reaction mixture was diluted with H2O, the layers were separated and the
aqueous layer extracted with CH2Cl2 (4 x 75 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered, and concentrated to give 78 as a colorless oil
(71.4 g, 100% yield). TLC (petroleum ether/ethyl acetate, 19:1): Rf = 0.44; [α]D26 +22.0 (c
0.97, CHCl3) {Ref.61a [α]D23 +28 (c 1.5, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.01, 0.03 (2 s, 3H each, SiCH3), 0.83 (s, 9H, SiC(CH3)
3), 1.17 (d, J = 6.1 Hz, 3H, H-4), 1.23 (t, J = 7.1 Hz, 3H, CH3), 2.33 (dd, J = 14.5, 5.3 Hz,
1H, H-2), 2.44 (dd, J = 14.5, 7.6 Hz, 1H, H-2), 4.04-4.13 (m, 2H, CH2), 4.21-4.29 (m, 1H,
H-3).
 13C NMR (100 MHz, CDCl3): δ = -5.1, -4.6 (SiCH3), 14.2 (CH3), 17.9 (SiC(CH3)3), 23.9
(C-4), 25.7 (SiC(CH3)3), 44.9 (C-2), 60.2 (CH2), 65.8 (C-3), 171.6 (C-1).
IR (neat): ν~  = 1739, 1255, 1183 cm-1.
(3S)-3-{[tert-Butyl(dimethyl)silyl]oxy}butanal (79)
To a solution of ester 78 (123 mg, 0.5 mmol) in CH2Cl2 (5 mL) was added DIBAL-
H (1.0 M in hexane, 0.55 mL, 0.55 mmol) dropwise at –78 °C. After being stirred for 0.5 h
at –78 °C, the temperature was raised to –30 °C, methanol (0.5 mL) was then added, the
cooling bath removed, and the mixture warmed to 0 °C. A saturated solution of potassium
sodium tartarte was added and the mixture was extracted with Et2O (3 x 5 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered and
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concentrated. The residue was purified by flash chromatography (petroleum ether/Et2O,
8:1) to yield 101 mg (100%) of aldehyde 79 as a colorless oil. The reaction also was
performed 12 g scale of ester 78 (12.3 g, 50 mmol) with DIBAL-H (1.0 M in hexane, 55
mL, 55 mmol) in CH2Cl2 (100 mL). In this case afforded 9.26 g (92%) of aldehyde 79.
TLC (petroleum ether/ethyl acetate, 6:1): Rf = 0.47; [α]D27 +14.0 (c 1.0, CHCl3) {Ref.62 [α]
D
23 +19 (c 2.0, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = -0.02, 0.00 (2 s, 3H each, SiCH3), 0.79 (s, 9H, SiC(CH3)
3), 1.16 (d, J = 6.2 Hz, 3H, H-4), 2.33 (dd, J = 15.9, 3.4 Hz, 1H, H-2), 2.47 (dd, J = 15.7,
2.5 Hz, 1H, H-2), 4.26-4.30 (m, H-3), 9.72 (s, 1H, H-1).
13C NMR (100 MHz, CDCl3): δ = -4.6, -4.0 (SiCH3), 18.3 (SiC(CH3)3), 24.6 (C-4), 26.1
(SiC(CH3)3), 53.4 (C-2), 64.9 (C-3), 202.7 (C-1).
IR (neat): ν~  = 2930, 1715, 1256 cm-1.
(2E,5S)-5-{[tert-Butyl(dimethyl)silyl]oxy}-2-hexen-1-ol (81)
To a solution of ester 62 (17.6 g, 68 mmol) in CH2Cl2 (150 mL) was added DIBAL-
H (1.0 M in hexane, 150 mL, 150 mmol) dropwise at –78 °C. After being stirred for 1.5 h
at –78 °C, the temperature was raised to –30 °C, methanol (2 mL) was added, and the
mixture allowed to reach 0 °C. Then a saturated solution of potassium sodium tartarte (100
mL) was added. The layers were separated and the aqueous layer extracted with Et2O (3 x
25 mL). The combined organic layers were washed with brine, dried (MgSO4), filtered and
concentrated. The crude product was purified by flash chromatography (petroleum
ether/Et2O, 4:1) to yield 15.0 g (96%) of alcohol 81 as a colorless oil. TLC (petroleum
ether/ethyl acetate, 4:1): Rf = 0.49; [α]D26 +6.04 (c 0.98, CHCl3).
1H NMR (400 MHz, CDCl3): δ = 0.02, 0.02 (2 s, 3H each, SiCH3), 0.86 (s, 9H, SiC(CH3)
3), 1.11 (d, J = 6.1 Hz, 3H, H-6), 1.62 (s, br, 1H, OH), 2.09-2.21 (m, 2H, H-4), 3.77-3.85
(m, 1H, H-5), 4.07 (d, J = 4.0 Hz, 1H, H-1), 5.63-5.67 (m, 2H, H-3, H-2).
13C NMR (100 MHz, CDCl3): δ = -4.6, -4.6 (SiCH3), 18.1 (SiC(CH3)3), 23.4 (C-6), 25.8
(SiC(CH3)3), 42.5 (C-4), 63.7 (C-1), 68.4 (C-5), 129.6 (C-2), 131.2 (C-3).
IR (neat): ν~  = 3343 (br), 2956, 2929, 1255 cm-1.
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[(1S,2R)-2-((2S)-2-{[tert-Butyl(dimethyl)silyl]oxy}propyl)cyclopropyl]methyl 
methanesulfonate (82)
Triethylamine (6.3 mL, 45 mmol) and methanesulfonyl chloride (1.75 mL, 22.5
mmol) were added to a cooled (0 °C) solution of the alcohol 61 (3.67 g, 15 mmol) in dry
CH2Cl2 (100 mL) under a nitrogen atmosphere. After being stirred for 30 min at 0 °C, the
mixture was diluted with ether, washed with H2O and brine. The organic layer was dried
(MgSO4), filtered, and concentrated to give 82 as a colorless oil (4.84 g). The residue was
used for the next reaction without further purification. TLC (petroleum ether/ethyl acetate,
4:1): Rf = 0.40; [α]D23 +7.89 (c 0.93, CHCl3).
1H NMR (400 MHz, CDCl3): δ = 0.03, 0.04 (2 s, 3H each, SiCH3), 0.45-0.56 (m, 2H,
cyclopropane CH2), 0.87 (s, 9H, SiC(CH3)3), 0.95-1.02 (m, 1H, H-2′), 1.14 (d, J = 6.0 Hz,
3H, CH3), 1.15-1.19 (m, 1H, CH2), 1.24 (s, br, 1H, H-1′), 1.56-1.62 (m, 1H, CH2), 2.99 (s,
3H, Ms CH3), 3.85 (q, J = 6.1 Hz, 1H, CHOR), 4.01-4.14 (m, 2H, CH2OMs).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.5 (SiCH3), 11.0 (cyclopropane CH2), 14.9
(cyclopropane C-2′), 17.4 (cyclopropane C-1′), 18.1 (SiC(CH3)3), 23.6 (CH3), 25.9 (SiC
(CH3)3), 37.9 (Ms CH3), 43.2 (CH2), 68.3 (CHOR), 74.7 (CH2OMs).
IR (neat): ν~  = 2956, 2930, 2858, 1255 cm-1.
HRMS: calcd. for C14H30O4SSiNa [M + Na]+ 345.15263, found 345.15299.
(1R,2R)-1-[(2S)-2-{[tert-Butyl(dimethyl)silyl]oxy}-propyl]-2-(iodomethyl)cyclopropane 
(83)
A solution of the crude sulfonate 82 (4.84 g, 15 mmol) in dry acetone (100 mL)
was treated with sodium iodide (4.84 g, 135 mmol) at 0 °C. After being stirred for 3 h at
room temperature, the mixture was diluted with petroleum ether (50 mL) and washed with
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H2O (50 mL). The aqueous phase was extracted with Et2O (3 x 30 mL). The combined
organic layers were washed with brine, dried (MgSO4), filtered and concentrated. The
residue was purified by flash chromatography (petroleum ether/Et2O, 8:1) to afford the
iodide 83 as a pale yellow oil (5.11 g, 96% from 61) which is used immediately for the
next step. TLC (petroleum ether/ethyl acetate, 60:1): Rf = 0.44.
1H NMR (400 MHz, CDCl3): δ = 0.04, 0.04 (2 s, 3H each, SiCH3), 0.42-0.46 (m, 1H,
cyclopropane CH2), 0.59-0.63 (m, 1H, cyclopropane CH2), 0.68-0.76 (m, 1H, cyclopropane
CH), 0.87 (s, 9H, SiC(CH3)3), 1.03-1.10 (m, 1H, CH2), 1.15 (d, J = 6.0 Hz, 3H, CH3), 1.24
(s, br, 1H, cyclopropane CH), 1.47-1.53 (m, 1H, CH2), 3.09-3.19 (m, 2H, CH2I), 3.85 (q, J
= 6.1 Hz, 1H, CHOR).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.5 (SiCH3), 13.7 (cyclopropane CH2), 17.9
(CH2I)., 18.1 (SiC(CH3)3), 22.1 (cyclopropane C-2′), 23.3 (cyclopropane C-1′), 23.6 (CH3),
25.9 (SiC(CH3)3), 43.8 (CH2), 68.4 (CHOR).
IR (neat): ν~  = 2956, 2928, 2857 cm-1.
HRMS: calcd. for C13H27OISiNa [M + Na]+ 377.07681, found 377.07665.
3-[(1R,3S)-3-{[tert-Butyl(dimethyl)silyl]oxy}-1-methylbutyl]-1,2,4-trioxolane (89)
Ozone was passed through the solution of alkene 60 (6.85 g, 30.0 mmol) in 100 mL
of CH2Cl2 (0.3 M) at -78 °C until a deep blue color appeared (2 h). The solution was kept
at –78 °C and nitrogen gas was passed through it until the color faded (2 h). The solution
was used for the next reaction without further purification. For analytical purposes, a
sample was carefully concentrated in vacuo. TLC (petroleum ether/ethyl acetate, 4:1): Rf =
0.40.
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.05 (s, 6H, SiCH3), 0.87 (s, 9H,
SiC(CH3)3), 0.97 (dd, J = 6.8, 2.3 Hz, 3H, CH3), 1.14 (d, J = 6.1 Hz, 3H, H-4′), 1.32-1.71
(m, 1H, H-2′), 2.04-2.12 (m, 1H, H-2′), 3.86-3.96 (m, 1H, H-1′), 4.93-4.96 (m, 1H, H-3),
5.00 (d, J = 3.8 Hz, 1H, H-5), 5.20 (d, J = 2.0 Hz, 1H, H-5).a
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13C NMR (100 MHz, CDCl3): δ = -4.9, -4.1 (SiCH3), 13.5 and 13.7 (CH3), 18.2 (SiC(CH3)
3), 24.4 (C-4′), 25.8 (SiC(CH3)3), 31.3 and 31.6 (C-1′), 41.2 and 41.4 (C-2′), 65.6 (C-3),
94.2 and 94.3 (C-5), 106.8 (C-3).a
Note: a) Some peaks are doubled since 60 is a mixture of diastereomers.
IR (neat): ν~  = 2957, 2930, 2886, 2858, 1463, 1255, 1084.
HRMS: calcd. for C13H28O4SiNa [M + Na]+ 299.16491, found 299.16494.
Methyl (2E,4R,6S)-6-{[tert-Butyl(dimethyl)silyl]oxy}-2,4-dimethylhept-2-enoate (91)
Methyl methacrylate (92) (222 µL 2.0 mmol) and alkene 60 (46 mg 0.2 mmol)
were added to solution of Grubbs catalyst 69 (8 mg, 10-2 mmol, 5 mol%) in CH2Cl2 (1
mL). The mixture was refluxed at 40 °C under nitrogen for 20 h. The reaction mixture was
then concentrated to about 0.5 mL and purified directly by flash chromatography
(petroleum ether/Et2O, 20:1) to afford the enoate 91 as a colorless oil (42 mg, 73%, only
trans was detected by 1H NMR spectroscopy). TLC (petroleum ether/ethyl acetate, 20:1):
Rf = 0.52; [α]D26 -6.98 (c 1.0, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.87 (s, 9H, SiC(CH3)3), 0.98 (d, J =
6.6 Hz, 3H, CH3), 1.10 (d, J = 6.0 Hz, 3H, H-7), 1.32-1.38 (m, 1H, H-5), 1.46-1.53 (m, 1H,
H-5), 1.83 (s, 3H, CH3), 2.58-2.69 (m, 1H, H-4), 3.72 (s, 3H, OCH3), 3.75-3.79 (m, 1H, H-
6), 6.57 (d, J = 9.9 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.2 (SiCH3), 12.4 (CH3C=CH), 18.0 (SiC(CH3)3),
19.5 (CH3CH), 24.0 (C-7), 25.8 (SiC(CH3)3), 29.7 (C-4), 46.5 (C-5), 51.7 (OCH3), 66.2 (C-
6), 125.7 (C-2), 148.2 (C-3), 168.9 (C-1).
IR (neat): ν~  = 2956, 2929, 2857, 1719, 1256 cm-1.
HRMS: calcd. for C16H32O3SiNa 323.20129, found 323.20125.
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(2E,4R,6S)-6-{[tert-Butyl(dimethyl)silyl]oxy}-2,4-dimethylhept-2-en-1-ol (93)
A solution of ester 91 (990 mg, 3.3 mmol) in CH2Cl2 (100 mL) was treated with
DIBAL-H (1.0 M in hexane, 7.3 mL, 7.3 mmol) in a dropwise fashion at -78 °C. After
stirring for 1.5 h at -78 °C, the temperature was raised to -30 °C, methanol (0.5 mL) was
added, and the mixture warmed up to 0 °C. The other workup manipulations were carried
out as described for the synthesis of 81. The crude product 93 was used without further
purification; yield 898 mg (100%), colorless oil. TLC (petroleum ether/ethyl acetate, 6:1):
Rf = 0.50; [α]D25 -1.94 (c 0.25, CHCl3) {Ref.17 [α]D24 -1.6 (c 0.91, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.04 (s, 6H, SiCH3), 0.88 (s, 9H, SiC(CH3)3), 0.93 (d, J =
6.6 Hz, 3H, CH3), 1.10 (d, J = 6.0 Hz, 3H, CH3), 1.26 (s, br, 1H, OH), 1.26-1.32 (m, 1H,
H-5), 1.41-1.48 (m, 1H, H-5), 1.66 (s, 3H, CH3), 2.47-2.54 (m, 1H, H-4), 3.73-3.81 (m,
1H, H-6), 3.97 (s, 2H, CH2OH), 6.57 (d, J = 9.9 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.2 (SiCH3), 13.7 (CH3C=CH), 18.1 (SiC(CH3)3),
20.5 (CH3CH), 24.0 (C-7), 25.9 (SiC(CH3)3), 28.6 (C-4), 47.5 (C-5), 66.5 (C-6), 69.0 (C-
1), 132.8 (C-3), 133.0 (C-2).
IR (neat): ν~  = 3336 (br), 2957, 2928, 2857, 1255 cm-1.
(2E ,4R ,6S ) -6-{ [ ter t -Butyl(dimethyl)s i ly l ]oxy}-2 ,4-dimethylhept-2-enyl  
methanesulfonate (94)
Triethylamine (340 µL, 1.25 mmol) and methanesulfonyl chloride (97 µL, 1.25
mmol) were added to a cooled (0 °C) solution of the alcohol 93 (221 mg, 0.81 mmol) in
dry CH2Cl2 (5 mL) under a nitrogen atmosphere. After being stirred for 30 min at 0 °C, the
mixture was diluted with Et2O (10 mL), washed with H2O, brine, dried (MgSO4), filtered
and concentrated in vacuo providing 275 mg (97%) of the crude mesylate 94 as a colorless
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oil. The crude product, containing around 10% of the corresponding chloride was used for
the next step without further purification. TLC (petroleum ether/ethyl acetate, 8:1): Rf =
0.54; [α]D24 -1.04 (c 1.00, CHCl3).
1H NMR (400 MHz, CDCl3): δ = 0.05 (s, 6H, SiCH3), 0.89 (s, 9H, SiC(CH3)3), 0.98 (d, J =
6.8 Hz, 3H, H-4a), 1.39 (d, J = 6.3 Hz, 3H, H-7), 1.50-1.55 (m, 1H, H-5), 1.59 (s, 3H, H-
2a), 1.71-1.78 (m, 1H, H-5), 2.46-2.54 (m, 1H, H-4), 2.97 (s, 3H, Ms CH3), 3.98 (s, 2H, H-
1), 4.73-4.78 (m, 1H, H-6), 5.18 (dd, J = 9.6, 2.6 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -5.3 (SiCH3), 13.5 (CH3C=CH), 18.4 (SiC(CH3)3), 20.8
(CH3CH), 21.3 (C-7), 25.9 (SiC(CH3)3), 28.6 (C-4), 38.6 (Ms CH3), 44.2 (C-5), 68.3 (C-6),
78.8 (C-1), 129.0 (C-3), 134.1 (C-2).
IR (neat): ν~  = 2956, 2930, 1353, 1175.
HRMS: calcd. for C16H34O4SSiNa [M + Na]+ 373.18393, found 373.18381.
(4R)-4-Benzyl-3-((2S,4E,6R,8S)-8-{[tert-butyl(dimethyl)silyl]oxy}-2,4,6-trimethylnon-
4-enoyl)-1,3-oxazolidin-2-one (96)
To a solution of propionyl-1,3-oxazolidin-2-one 75 (173 mg, 0.74 mmol) in THF
(20 mL) was added sodium hexamethyldisilazide (0.4 mL, 2.0 M in THF, 0.8 mmol) at -78
°C. The solution was then stirred at -78 °C for 2 h before a solution of iodide 59 (264 mg,
0.64 mmol) in THF (3 mL) was added. The reaction was allowed to proceed at -78 °C for
15 h, then the mixture was allowed to reach 0 °C. Thereafter, the mixture was partitioned
between saturated NH4Cl (10 mL) and Et2O (10 mL). The layers were separated and the
aqueous layer was extracted with Et2O (2 x 50 mL). The combined organic extracts were
dried (MgSO4), filtered, and concentrated to yield a white amorphous solid. The crude
product was purified by flash chromatography (petroleum ether/Et2O, 6:1) to afford the
alkylation product 96 as a sticky colorless oil (190 mg, 61%) and recovered iodide 59
(24%). TLC petroleum ether/ethyl acetate, 6:1): Rf = 0.54; [α]D25 -30.0 (c 0.94, CHCl3)
{Ref.17 [α]D24 -35.2 (c 0.94, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.06 (s, 6H, SiCH3), 0.89 (d, J = 6.6 Hz, 3H, CH3), 0.90
(s, 9H, SiC(CH3)3), 1.11 (d, J = 5.8 Hz, 3H, H-9′), 1.12 (d, J = 6.8 Hz, 3H, CH3), 1.27-1.34
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(m, 1H, H-7′), 1.43-1.50 (m, 1H, H-7′), 1.68 (s, 3H, CH3), 1.97-2.03 (m, 1H, H-3′), 2.46-
2.50 (m, 1H, H-6′), 2.52 (m, 1H, H-3′), 2.69-2.75 (m, 1H, benzylic H), 3.26-3.30 (m, 1H,
benzylic H), 3.75-3.82 (m, 1H, H-8′), 3.92-4.01 (m, 1H, H-2’), 4.13-4.20 (m, 2H, H-5),
4.66-4.72 (m, 1H, H-4), 5.03 (d, J = 9.4 Hz, 1H, H-5′), 7.21-7.35 (m, 5H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = -4.9, -4.5 (SiCH3), 15.4 (C-4a′), 16.0 (C-2a′), 18.0 (SiC
(CH3)3), 20.8 (C-6a′), 23.6 (C-9′), 25.8 (SiC(CH3)3), 29.0 (C-6′), 35.4 (C-2′), 38.0
(CH2C6H5), 43.9 (C-3′), 47.5 (C-7′), 55.2 (C-4), 66.6 (C-5), 68.5 (C-8′), 127.2, 128.8,
129.3 (aromatic C), 130.1 (C-4′), 134.4 (C-5′), 135.3 (aromatic C), 153.0 (C-2), 177.0 (C-
1′).
IR (neat): ν~  = 2956, 2929, 1783, 1387 cm-1.
5.3 Alternative Approach to 8-Hydroxy Acid and Derivatives
(S)-Ethyl 3-hydroxyheptanoate (108)
A. [(S)-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl]ruthenium(II) complex.
A Schlenk tube was charged with [RuCl2(benzene) 2] (11 mg, 2.2 x 10-2 mmol) and
(S)-BINAP (107) (28 mg, 4.5 x 10-2 mmol). DMF (1 mL) was introduced with a
hypodermic syringe and the suspension was stirred at 100 °C for 10 min, giving a clear
reddish brown solution. The reaction mixture was cooled and concentrated at 1 mm at 50 °
C with vigorous stirring and then at 0.1 mm for 1 h to give (S)-BINAP-Ru(II) complex as a
reddish brown solid. This complex was used as the hydrogenation catalyst.
B. Hydrogenation of ethyl 3-oxoheptanoate (106)
The Schlenk tube was charged with ethyl 3-oxoheptanoate (106) (17.2 g, 100 mol)
and methanol (17 mL). To this mixture was added a solution of the in situ prepared (S)-
BINAP-Ru(II) complex (from A) in methanol (2 mL) via hypodermic syringe, and the
flask was rinsed with MeOH (2 mL). The resulting yellowish orange solution was
transferred by cannula to an autoclave, and the flask was rinsed with MeOH (2 x 5 mL).
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The autoclave was equipped with a gas inlet tube, a septa-covered stop valve, and pressure
gauge. The gas inlet tube was attached to a hydrogen source. Hydrogen was introduced
into the reaction vessel while the internal temperature was 95 °C. The pressure was
carefully released to 1 atm by opening the stop valve. This procedure was repeated three
times, and finally hydrogen was pressurized to 5.75 bar. The solution was stirred at 95 °C
for 23 h during which time the hydrogen cylinder was kept connected. After the main valve
of the hydrogen cylinder had been closed, the reaction mixture was allowed to cool to
room temperature, excess hydrogen was carefully bled off, and the apparatus was
disassembled. The solvent was removed from the reaction mixture by a rotary evaporator.
The crude product was purified by distillation to give a colorless oil 15.8 g (91% yield) of
108 in 93% ee as a fraction boiling at 55-60 °C, 6 x 10-3 mbar. TLC (petroleum ether/ethyl
acetate, 4:1): Rf = 0.54.    
1H NMR (400 MHz, CDCl3): δ = 0.86 (t, J = 7.0 Hz, 3H, H-7), 1.23 (t, J = 7.1 Hz, 3H,
CH3), 1.26-1.35 (m, 2H, H-6), 1.26-1.44 (m, 2H, H-5), 1.35-1.53 (m, 2H, H-4), 2.32-2.48
(m, 2H, H-2), 3.33 (s, 1H, OH), 3.92-3.98 (m, 2H, H-3), 4.13 (q, J = 7.1 Hz, 2H, CH2).
13C NMR (100 MHz, CDCl3): δ = 13.9 (C-7), 14.1 (CH3), 22.5 (C-6), 27.6 (C-5), 36.1 (C-
4), 41.3 (C-2), 60.6 (CH2), 67.9 (C-3), 173.0 (C-1).
IR (neat): ν~  = 3369 (br), 2974, 1710, 1516, 1166 cm-1.
Ethyl (3S)-3-{[tert-butyl(dimethyl)silyl]oxy}heptanoate (109)
To a stirred solution of alcohol 108 (15.7 g, 90 mmol) in CH2Cl2 (100 mL) was
added imidazole (12.2 g, 180 mmol) at 0 °C and the mixture stirred for 5 min resulting in a
homogeneous solution. Subsequently, tert-butyldimethylsilyl chloride (16.3 g, 108 mmol)
was added and the whole mixture stirred for 0.5 h at 0 °C and then at room temperature for
23 h. The reaction mixture was diluted with H2O, the layers were separated and the
aqueous layer was extracted with CH2Cl2 (4 x 25 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was
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purified by short flash chromatography (petroleum ether/Et2O, 1:1) to yield 109 as a pale
yellow oil (25.4 g, 98%). TLC (petroleum ether/ Et2O, 20:1): Rf = 0.48.
1H NMR (400 MHz, CDCl3): δ = 0.01, 0.04 (2 s, 3H each, SiCH3), 0.84 (s, 9H, SiC(CH3)
3), 0.86-0.89 (m, 3H, H-7), 1.24 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.27-1.29 (m, 4H, H-5, H-
6), 1.44-1.49 (m, 2H, H-4), 2.39-2.41 (m, 2H, H-2), 4.07-4.13 (m, 3H, H-3, OCH2CH3).
13C NMR (100 MHz, CDCl3): δ = -4.6 (SiCH3), 14.0 (C-7), 14.2 (OCH2CH3), 18.0 (SiC
(CH3)3), 22.7 (C-6), 25.8 (SiC(CH3)3), 27.1 (C-5), 37.3 (C-4), 42.7 (C-2), 60.2
(OCH2CH3), 69.5 (C-3), 171.9 (C-1).
IR (neat): ν~  = 2958, 2931, 2858, 1739, 1255, 1094 cm-1.
HRMS: calcd. for C15H32O3SiNa 311.20129, found 311.20135.
(3S)-3-{[tert-Butyl(dimethyl)silyl]oxy}heptanal (110)
To a solution of ester 109 (4.97 g, 17.2 mmol) in CH2Cl2 (140 mL) was added
DIBAL-H (1.0 M in hexane, 19 mL, 19 mmol) dropwise at -78 °C. After being stirred for
0.5 h at -78 °C, the temperature was raised to -30 °C. After the reaction was complete by
TLC, methanol (0.5 mL) was added, the cooling bath removed, and the mixture warmed to
0 °C. A saturated solution of potassium sodium tartarte was added and the mixture was
stirred until it became clear. The layers were separated and the aqueous layer was extracted
with CH2Cl2 (3 x 25 mL). The combined organic layers were washed with brine, dried
(MgSO4), filtered and concentrated. The residue was purified by short flash
chromatography (petroleum ether/Et2O, 7:1) to yield 2.94 g (70%) of aldehyde 110 as a
colorless oil. TLC (petroleum ether/ethyl acetate, 20:1): Rf = 0.45; [α]D27 +1.90 (c 0.18,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.04, 0.05 (2 s, 3H each, SiCH3), 0.85 (s, 9H, SiC(CH3)
3), 0.88 (t, J = 6.8 Hz, 3H, H-7), 1.25-1.33 (m, 4H, H-5, H-6), 1.48-1.54 (m, 2H, H-4), 2.50
(dd, J = 5.7, 2.4 Hz, 2H, H-2), 4.13-4.19 (m, 1H, H-3), 9.79 (t, J = 2.4 Hz, 1H, H-1).
13C NMR (100 MHz, CDCl3): δ = -4.7, -4.5 (SiCH3), 14.0 (C-7), 18.0 (SiC(CH3)3), 22.6
(C-6), 25.7 (SiC(CH3)3), 27.3 (C-5), 37.5 (C-4), 50.8 (C-2), 68.2 (C-3), 202.5 (C-1).
IR (neat): ν~  = 2957, 2931, 2858, 1727, 1472, 1255 cm-1.
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Methyl (2E,5S)-5-{[tert-butyl(dimethyl)silyl]oxy}-2-nonenoate (111)
A mixture of the aldehyde 110 (6.34 g, 25.9 mmol) and carbomethoxymethylene
triphenylphosphorane (80) (10.4 g, 31.1 mmol) in benzene (60 mL) was refluxed overnight
(80 °C, 19 h). The precipitated solids were filtered and washed with cold (0 °C) Et2O. The
filtrate was concentrated and the residue purified by chromatography (petroleum
ether/Et2O, 15:1) to afford the enoate 111 as a pale yellow oil (7.06 g, 86%, E isomer was
exclusively separated). TLC (petroleum ether/ethyl acetate, 20:1): Rf = 0.43; [α]D27 -2.69
(c 1.03, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.02, 0.02 (2 s, 3H each, SiCH3), 0.84-0.89 (m, 3H, H-
9), 0.86 (s, 9H, SiC(CH3)3), 1.25-1.32 (m, 4H, H-7, H-8), 1.39-1.44 (m, 2H, H-6), 2.29-
2.35 (m, 2H, H-4), 3.71 (s, 3H, OCH3), 3.73-3.77 (m, 1H, H-5), 5.82 (d, J = 15.7 Hz, 1H,
H-2), 6.96 (dt, J = 15.7, 7.2 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = -4.6 (SiCH3), 14.1 (C-9), 18.1 (SiC(CH3)3), 22.7 (C-8),
25.8 (SiC(CH3)3), 27.5 (C-7), 36.9 (C-6), 46.2 (C-4), 51.3 (OCH3), 71.2 (C-5), 122.7 (C-2),
146.4 (C-3), 166.9 (C-1).
IR (neat): ν~  = 2956, 2931, 2858, 1729, 1659, 1257 cm-1.
HRMS: calcd. for C16H32O3SiNa 323.21129, found 323.20127.
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(2E,5S)-5-{[tert-Butyl(dimethyl)silyl]oxy}-2-nonen-1-ol (112)
To a solution of ester 111 (2.49 g, 8.28 mmol) in CH2Cl2 (20 mL) was added
DIBAL-H (1.0 M in hexane, 18 mL, 18 mmol) dropwise at -78 °C. After being stirred for
0.5 h at -78 °C, the temperature was raised to -30 °C. After the reaction was complete by
TLC, methanol (1 mL) was added, and the mixture allowed to reach 0 °C. Then a saturated
solution of potassium sodium tartarte (100 mL) was added. The layers were separated and
the aqueous layer was extracted with CH2Cl2 (3 x 10 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered and concentrated. The crude product was
purified by flash chromatography (petroleum ether/Et2O, 1:1) to yield 2.17 g (96%) of
alcohol 112 as a colorless oil. TLC (petroleum ether/ethyl acetate, 6:1): Rf = 0.40; [α]D27 -
6.46 (c 1.06, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.02, (s, 6H, SiCH3), 0.85-0.89 (m, 3H, H-7, H-9), 0.86
(s, 9H, SiC(CH3)3), 1.24-1.32 (m, 4H, H-7, H-8), 1.38-1.43 (m, 2H, H-6), 1.62 (s, br, 1H,
OH), 2.14-2.22 (m, 2H, H-4), 3.63-3.68 (m, 1H, H-5), 4.08 (d, J = 4.6 Hz, 2H, H-1), 5.63-
5.68 (m, 2H, H-3, H-2).
13C NMR (100 MHz, CDCl3): δ = -4.6 (SiCH3), 14.1 (C-9), 18.1 (SiC(CH3)3), 22.8 (C-8),
25.9 (SiC(CH3)3), 27.6 (C-7), 36.5 (C-6), 40.1 (C-4), 63.7 (C-1), 72.0 (C-5), 129.6 (C-2),
131.1 (C-3).
IR (neat): ν~  = 3322 (br), 2956, 2930, 2858, 1255 cm-1.
HRMS: calcd. for C15H32O3SiNa 295.20638, found 295.20630.
[(1S,2R)-2-((2S)-2-{[tert-Butyl(dimethyl)silyl]oxy}hexyl)cyclopropyl]methanol (113)
To a solution of CH2Cl2 (100 mL) and 1,2-dimethoxyethane (DME) (2.6 mL, 25
mmol) was added a solution of diethylzinc (0.88 M in hexane, 28 mL, 25 mmol) at -10 °C
followed by the dropwise addition of CH2I2 (4.0 mL, 50 mmol) over 15-20 min while
OTBS
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maintaining the internal temperature between -8 and -12 °C. After complete addition, the
resulting clear solution was stirred for 10 min at -10 °C before a solution of dioxaborolane
ligand 67 (4.05 g, 15 mmol) in CH2Cl2 (15 mL, 1.0 M) was added via cannula over a 15-20
min period while maintaining the internal temperature below -5 °C. This was followed by
the dropwise addition of alcohol 112 (3.41 g, 12.5 mmol), dissolved in CH2Cl2 (15 mL)
while maintaining the internal temperature below -5 °C. After being stirred for 0.5 h at -10
°C, the mixture was allowed to reach room temperature and stirred for 19 h. The reaction
was quenched with saturated NH4Cl solution (10 mL) and 10% of HCl (40 mL) and the
mixture was extracted with Et2O (3 x 25 mL). The combined organic layers were added to
a mixture of 2 N NaOH (60 mL) and H2O2 (30%, 10 mL). The biphasic solution was stirred
for 5 min and then the layers were separated. The organic phase was washed with 10% of
HCl (50 mL), Na2SO3 (50 mL), NaHCO3 (50 mL), and brine (50 mL). After drying
(MgSO4), filtration and concentration of the organic layer under reduced pressure, the
crude product was purified by flash chromatography (petroleum ether/Et2O, 6:1) to afford
113 as a colorless oil (3.20 g, 89%, >95% de). TLC (petroleum ether/ethyl acetate, 4:1): Rf
= 0.45; [α]D27 +9.64 (c 1.10, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.01, 0.02 (2 s, 3 H each, SiCH3), 0.25-0.30 (m, 1H,
cyclopropane CH2), 0.32-0.37 (m, 1H, cyclopropane CH2), 0.63-0.70 (m, 1H, H-2′), 0.86
(s, 9H, SiC(CH3)3), 0.86-0.87 (m, 2H, H-1′), 1.23-1.30 (m, 5H, H-1′′, H-4′′, H-5′′), 1.41-
1.55 (m, 3H, H-1′′, H-3′′), 1.99 (s, br, 1H, OH), 3.33-3.38 (m, 1H, CH2OH), 3.45-3.49 (m,
1H, CH2OH), 3.57-3.61 (m, 1H, CHOR).
13C NMR (100 MHz, CDCl3): δ = -4.6 (SiCH3), 9.9 (cyclopropane CH2), 13.4
(cyclopropane C-2′), 14.1 (CH3), 18.1 (SiC(CH3)3), 21.2 (cyclopropane C-1′), 22.8 (C-5′′),
25.9 (SiC(CH3)3), 27.5 (C-4′′), 36.6 (C-3′′), 41.0 (C-1′′), 67.0 (CH2OH), 72.4 (CHOR).
IR (neat): ν~  = 3351 (br), 2937, 2866, 1462, 1373, 1254, 1053 cm-1.
HRMS: calcd. for C16H34O2SiNa 309.22203, found 309.22201.
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(S)-Epichlorohydrin ((S)-121)
A. [(R,R)-N,N′-Bis(3,5-di-tert-butylsalicylidene)-1,2-cyclohexanediaminato(2-)]cobalt(II)
A solution of cobalt(II) acetate tetrahydrate (1.49 g, 6.0 mmol) in MeOH (20 mL)
was added to a solution of ligand [(R,R)-N,N′-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediamine ((R,R)-119) (2.73 g, 5 mmol) in CH2Cl2 (20 mL) via cannula, and the
flask was rinsed with MeOH (5 mL). A brick-red solid began to precipitate before addition
was complete. The mixture was allowed to stir for 15 min at room temperature and then 30
min at 0 °C. Precipitated solids were filtered and rinsed with cold (0 °C) MeOH (2 x 10
mL). The red solid was dried in vacuo to yield the desired product as a red amorphous
solid (2.95 g, 49 mmol, 98%). The catalyst was used for the next step without further
purification.
B. Hydrolytic kinetic resolution of epichlorohydrin ((±)-121)
A solution of the catalyst [(R,R)-N,N′-bis(3,5-di-tert-butylsalicylidene)-1,2-
cyclohexanediaminato(2-)]cobalt(II) (from A) (1.2 g, 2 mmol, 0.005 equiv) in CH2Cl2 (20
mL) was treated with acetic acid (1.2 mL). The crude catalyst residue obtained after
concentration was treated with with (±)-epichlorohydrin (31 mL, 400 mmol) in THF (4
mL). The solution was cooled to -30 °C, and then treated with H2O (4 mL, 220 mmol, 0.55
equiv) and the temperature was raised up to 0 °C and stirring continured at that temperature
for 16 h. The crude product was purified by distillation at 25 °C (0.1 mbar) into a cooled (-
30 °C) receiving flask, to give a solution of (S)-epichlorohydrin ((S)-121) in THF (amount
of product calculated by 1H-NMR, as 12.7 g, 137 mmol, 35% yield, >99% ee).
1H NMR (400 MHz, CDCl3): δ = 2.66-2.68 (m, 1H, H-3), 2.87-2.89 (m, 1H, H-3), 3.21-
3.25 (m, 1H, H-2), 3.56 (d, J = 5.3 Hz, 1H, H-1′).
13C NMR (100 MHz, CDCl3): δ = 45.0 (C-1′), 46.9 (C-3), 51.2 (C-2).
O
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(2S)-2-(4-Methoxybenzyl)oxirane ((S)-123)
A solution of p-anisolbromide (0.35 mL, 2.75 mmol) in dry THF (5 mL) was
treated with t-BuLi (1.5 M in pentane, 5 mL, 7.5 mmol) at 0 °C. The resulting mixture was
stirred at 0 °C for 5 min, then the temperature was raised to room temperature. The
resultant solution was stirred at room temperature for 30 min, before a solution of (S)-
epichlorohydrin ((S)-121) (0.2 mL, 2.5 mmol) in THF (0.3 mL) was added at -78 °C. The
solution was allowed to warm to room temperature and stirred for 2 h. The reaction was
quenched with saturated NH4Cl solution (5 mL). The layers were separated and the
aqueous layer was extracted with Et2O (3 x 5 mL). The combined organic layers were
washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was
purified by distillation to give a colorless oil 279 mg (68% yield) of (S)-123 as a fraction
boiling at 74-82 °C, 6 x 10-3 mbar. TLC (petroleum ether/ethyl acetate, 4:1): Rf = 0.56; [α]
25
D -7.76 (c 1.06, CH2Cl2). {Ref.146 [α]D20 +0.9 (c 1.0, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 2.51-2.53 (m, 1H, H-3), 2.73-2.78 (m, 1H, H-1′), 2.76-
2.78 (m, 1H, H-3), 2.84-2.89 (m, 1H, H-1′), 3.09-3.13 (m, 1H, H-2), 3.79 (s, 3H, OCH3),
6.85 (d, J = 8.6 Hz, 2H, aromatic H), 7.16 (d, J = 8.6 Hz, 2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = 37.8 (C-1′), 46.8 (C-3), 52.6 (C-2), 55.2 (OCH3), 113.9,
129.1, 130.0, 158.4 (aromatic C).
IR (neat) ν~ = 3046, 2995, 2836, 1613, 1513, 1247, 1178, 1035.
O
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(2S)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-(1,3-dithian-2-yl)-3-(4-methoxyphenyl)
propane (126)
A solution of tert-butyl(1,3-dithian-2-yl)dimethylsilane (124)105 (13.4 g, 57 mmol)
in Et2O (100 mL) was cooled to -78 °C, and t-BuLi (1.5 M in pentane, 40 mL, 60 mmol)
was added dropwise over 15 min. The resultant solution was stirred at -45 °C for 15 min
before a solution of (2S)-2-(4-methoxybenzyl)oxirane ((S)-123) (8.88 g, 54 mmol) in Et2O
(10 mL) was added at -78 °C. The solution was allowed to stir for 15 min at -78 °C and
then 1.5 h at -25 °C. At this point HMPA (3.8 mL, 22 mmol) was added at -78 °C and then
the cooling bath was removed. The reaction was stirred at room temperature for 14 h as a
dark red color developed. After TLC indicated completion of the silyl rearrangement, the
reaction was quenched with saturated NH4Cl solution (50 mL) at 0 °C. The aqueous layer
was extracted with Et2O (3 x 50 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered, and concentrated. The residue was purified by
chromatography (petroleum ether/Et2O, 11:1) to afford the dithiane 126 as a pale yellow
oil (16.1 g, 75% yield) TLC (petroleum ether/ethyl acetate, 16:1): Rf = 0.43; [α]D25 +24.6
(c 1.08, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.07, 0.07 (2 s, 3H each, SiCH3), 0.88 (s, 9H, SiC(CH3)
3), 1.75-1.87 (m, 3H, 2 x H-1′, H-5), 2.04-2.11 (m, 1H, H-5), 2.63-2.89 (m, 6H, H-3′, H-4,
H-6), 3.77 (s, 3H, CH3), 4.06-4.14 (m, 2H, H-2, H-2′), 6.80 (d, J = 8.6 Hz, 2H, aromatic
H), 7.07 (d, J = 8.6 Hz, 2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.7 (SiCH3), 18.0 (SiC(CH3)3), 25.9 (3C, TBS-C
(CH3)3), 26.0 (C-5), 29.9 (C-6), 30.5 (C-4), 42.2 (C-1′), 43.4 (C-3′), 44.0 (C-2′), 55.2
(OCH3), 70.0 (C-2′), 113.6, 130.2, 130.5, 158.1 (aromatic C).
IR (neat) ν~  = 2930, 2855, 1611, 1512, 1247, 1178, 1083, 1038.
HRMS: calcd. for C20H34O2S2SiNa 421.16617, found 421.16644.
MeO
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(3S)-3-{[tert-Butyl(dimethyl)silyl]oxy}-4-(4-methoxyphenyl)butanal (127)
A mixture of dithiane (126) (7.98 g, 20 mmol), CaCO3 (4.91 g, 49 mmol), CH3I (50 mL) in
CH3CN (500 mL) and H2O (220 mL) was stirred with protection from light for 23 h at
room temperature. The mixture was extracted with ethyl acetate (2 x 300 mL). The
combined organic layers were washed with brine, dried (MgSO4), filtered and
concentrated. The residue was purified by filtration through a short column of celite. The
filter celite was washed with ethyl acetate and the combined filtrate was concentrated to
yield aldehyde 127 (5.76 g, 93%) as a pale yellow oil. The product was used for the next
step without further purification. TLC (petroleum ether/ethyl acetate, 8:1): Rf = 0.56; [α]
24
D -6.74 (c 1.01, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.08, 0.01 (2 s, 3H each, SiCH3), 0.85 (s, 9H, SiC(CH3)
3), 2.48 (dd, J = 5.7, 2.4 Hz, 2H, H-2), 2.68-2.73 (s, 1H, H-4), 2.78-2.83 (m, 1H, H-4), 3.77
(s, 3H, OCH3), 4.29-4.35 (m, 1H, H-3), 6.82 (d, J = 8.6 Hz, 2H, aromatic H), 7.07 (d, J =
8.6 Hz, 2H, aromatic H), 9.75 (t, J = 2.4 Hz, 2H, H-1).
13C NMR (100 MHz, CDCl3): δ = -5.0, -4.8 (SiCH3), 17.9 (SiC(CH3)3), 25.7 (SiC(CH3)3),
43.5 (C-4), 50.3 (C-2), 55.2 (OCH3), 69.7 (C-3), 113.8, 129.8, 130.6, 158.3  (aromatic C),
202.1 (C-1).
IR (neat) ν~  = 2954, 2930, 2856, 1726, 1613, 1513, 1249, 1101.
Methyl (2E,5R)-5-{[tert-butyl(dimethyl)silyl]oxy}-6-(4-methoxyphenyl)-2-hexenoate
(128)
A mixture of the aldehyde 127 (10.1 g, 34 mmol) and carbomethoxymethylene
triphenylphosphorane (80) (13.6 g, 40.8 mmol) in benzene (340 mL) was refluxed
overnight (80 °C, 13 h). The resulting precipitate was removed by filtration and washed
MeO
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with Et2O. The filtrate was concentrated and the residue purified by chromatography
(petroleum ether/Et2O, 11:1) to afford the enoate 128 as a pale yellow oil (11.0 g, 93%,
trans/cis, 93:7 as determined by relative peak heights in the 1H NMR spectrum). TLC
(petroleum ether/ethyl acetate, 8:1): Rf = 0.54; [α]D25 -5.4 (c 1.08, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.17, -0.04 (2 s, 3H each, SiCH3), 0.85 (s, 9H, SiC(CH3)
3), 2.23-2.37 (m, 2H, H-4), 2.67 (dd, J = 6.5, 2.7 Hz, 2H, H-6), 3.72 (s, 3H, CO2CH3), 3.77
(s, 3H, C6H4OCH3), 3.90-3.92 (m, 1H, H-5), 5.82 (d, J = 15.7 Hz, 1H, H-2), 6.81 (d, J =
8.6 Hz, 2H, aromatic H), 6.99 (dt, J = 15.7, 7.6 Hz, 1H, H-3), 7.06 (d, J = 8.6 Hz, 2H,
aromatic H).
13C NMR (100 MHz, CDCl3): δ = -4.9 (SiCH3), 18.0 (SiC(CH3)3), 25.8 (SiC(CH3)3), 39.6
(C-4), 43.0 (C-6), 51.4 (CO2CH3), 55.2 (C6H4OCH3), 72.7 (C-5), 113.6 (aromatic C), 123.0
(C-2), 130.5, 130.6 (aromatic C), 146.1 (C-3), 158.1 (aromatic C), 166.8 (C-1).
IR (neat): ν~  = 2953, 2930, 2857, 1726, 1513, 1249 cm-1.
HRMS: calcd. for C20H32O4SiNa 387.19621, found 387.19627.
(2E,5R)-5-{[tert-Butyl(dimethyl)silyl]oxy}-6-(4-methoxyphenyl)-2-hexen-1-ol (129)
To a solution of ester 128 (15.3 g, 41.9 mmol) in CH2Cl2 (84 mL) was added
DIBAL-H (1.0 M in hexane, 92 mL, 92 mmol) dropwise at -78 °C over 15 min. After being
stirred for 2 h at -78 °C, the temperature was raised to -10 °C, methanol (2 mL) was added,
and the mixture allowed to reach 0 °C. Then a saturated solution of potassium sodium
tartarte (100 mL) was added. The layers were separated and the aqueous layer was
extracted with CH2Cl2 (3 x 30 mL). The combined organic layers were washed with brine,
dried (MgSO4), filtered and concentrated. The crude product was purified by flash
chromatography (petroleum ether/Et2O, 1:2) to yield 13.0 g (92%) of alcohol 129 as a pale
yellow oil. TLC (petroleum ether/ethyl acetate, 3:1): Rf = 0.45; [α]D26 -12.7 (c 0.95,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.20, -0.06 (2 s, 3H each, SiCH3), 0.84 (s, 9H, SiC(CH3)
3), 2.12-2.25 (m, 2H, H-4), 2.59-2.70 (m, 1H, H-6), 3.77 (s, 3H, CH3), 3.81-3.84 (m, 1H,
MeO
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H-5), 4.10 (d, J = 5.3 Hz, 2H, H-1), 5.61-5.76 (m, 2H, H-2, H-3), 6.80 (d, J = 8.6 Hz, 2H,
aromatic H), 7.06 (d, J = 8.6 Hz, 2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = -5.0, -4.8 (SiCH3), 18.1 (SiC(CH3)3), 25.8 (SiC(CH3)3),
39.8 (C-4), 42.7 (C-6), 55.2 (CH3), 63.8 (C-1), 73.5 (C-5), 113.5 (aromatic C), 129.3 (C-3),
130.7, 131.1 (aromatic C), 131.5 (C-2), 158.0 (aromatic C).
IR (neat): ν~  = 3352 (br), 2954, 2929, 2856, 1513, 1248 cm-1.
HRMS: calcd. for C19H32O3SiNa 359.20129, found 359.20119.
[(1S,2R)-2-(3-(2R)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-(4-methoxyphenyl)propyl) 
cyclopropyl]methanol (130)
To a mixture of CH2Cl2 (300 mL) and 1,2-dimethoxyethane (DME) (8.2 mL, 78.8
mmol) was added a solution of diethylzinc (1.0 M in hexane, 90 mL, 90 mmol) at -10 °C
followed by the dropwise addition of CH2I2 (13 mL, 158 mmol) over 15 min while
maintaining the internal temperature between -8 and -12 °C. After complete addition, the
resulting clear solution was stirred for 10 min at -10 °C before a solution of dioxaborolane
ligand 67 (12.8 g, 47.3 mmol) in CH2Cl2 (47 mL, 1.0 M) was added via cannula over a 10
min while maintaining the internal temperature below -5 °C. This was followed by the
dropwise addition of allylic alcohol 129 (13.5 g, 39.4 mmol), dissolved in CH2Cl2 (40 mL)
while maintaining the internal temperature below -5 °C. After being stirred for 0.5 h at -10
°C, the mixture was allowed to reach room temperature and stirred for 17 h. The reaction
was quenched with saturated NH4Cl solution (30 mL) and 10% of HCl (120 mL) and the
mixture was extracted with Et2O (3 x 75 mL). The combined organic layers were added to
a mixture of 2 N NaOH (180 mL) and H2O2 (30%, 30 mL). The biphasic solution was
stirred for 5 min and then the layers were separated. The organic phase was washed with
10% of HCl (150 mL), Na2SO3 (150 mL), NaHCO3 (150 mL), and brine (150 mL). After
drying (MgSO4), filtration and concentration of the organic layer under reduced pressure,
the crude product was purified by flash chromatography (petroleum ether/Et2O, 1:4) to
afford 130 as a colorless oil (13.25 g, 96%, the diastereomeric ratio was determined in the
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next step). TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.52; [α]D28 +6.17 (c 0.95,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.18, -0.05 (2 s, 3H each, SiCH3), 0.24-0.28 (m, 1H,
cyclopropane CH2), 0.35-0.39 (m, 1H, cyclopropane CH2), 0.67-0.75 (m, 1H, H-2′), 0.82-
0.86 (m, 2H, H-1′), 0.85 (s, 9H, SiC(CH3)3), 1.23-1.30 (m, 1H, H-1′′), 1.45-1.52 (m, 1H,
H-1′′), 1.91 (s, br, 1H, OH), 2.66-2.78 (m, 2H, H-3′′), 3.39-3.50 (m, 2H, CH2OH), 3.80-
3.88 (m, 1H, H-2′′), 6.79 (d, J = 8.6 Hz, 2H, aromatic H), 7.07 (d, J = 8.6 Hz, 2H, aromatic
H).
13C NMR (100 MHz, CDCl3): δ = -4.9, -4.8 (SiCH3), 10.0 (cyclopropane CH2), 13.5
(cyclopropane C-2′), 18.0 (SiC(CH3)3), 21.3 (cyclopropane C-1′), 25.9 (SiC(CH3)3), 40.8
(C1′′), 42.9 (C3′′), 55.2 (CH3), 67.0 (CH2OH), 74.0 (CHOR), 113.5, 130.6, 131.4, 157.9
(aromatic C).
IR (neat): ν~  = 3349 (br), 2954, 2929, 2857, 1513, 1248 cm-1.
HRMS: calcd. for C20H34O3SiNa 373.21694, found 373.21684.
(1R,2R)-1-[3-(2R)-2-{[tert-Butyl(dimethyl)silyl]oxy}-1-(4-methoxyphenyl)propyl]-2-
(iodomethyl)cyclopropane (133)
A mixture of triphenyl phosphite (4.0 mL, 15 mmol) and methyl iodide (1.25 mL,
20 mmol) was heated under gentle reflux until the internal temperature had risen to about
120 °C (over 6 h). The reaction mixture was stirred in the dark for 16 h at 120 °C. At this
point the mixture was dark and viscous. The reaction mixture was allowed to cool to room.
The alcohol 130 was added to the with the previously prepared methyl
triphenoxyphosphonium iodide. The mixture was vigorously stirred until it became
homogeneous and allowed to stand overnight (14 h) at room temperature. The crude
reaction mixture was purified by chromatography (petroleum ether/ethyl acetate, 50:1) to
afford the iodide 133 as a pale yellow oil (2.19 g, 48% yield) which is used immediately
MeO
TBSO
I
110 EXPERIMENTAL PART
for the next step. TLC (petroleum ether/ethyl acetate, 20:1): Rf = 0.56; [α]D26 +1.66 (c
0.65, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.21, -0.07 (2 s, 3H each, SiCH3), 0.44-0.48 (m, 1H,
cyclopropane CH2), 0.55-0.60 (m, 1H, cyclopropane CH2), 0.74-0.79 (m, 1H, H-2′), 0.83
(s, 9H, SiC(CH3)3), 1.02-1.10 (m, 1H, H-1′), 1.28-1.44 (m, 2H, H-1′′), 2.63-2.68 (m, 1H,
H-3′), 2.78-2.82 (m, 1H, H-3′), 3.10-3.20 (m, 2H, H-1), 3.78 (s, 3H, CH3), 3.82-3.88 (m,
1H, H-2′′), 6.80 (d, J = 8.4 Hz, 2H, aromatic H), 7.10 (d, J = 8.6 Hz, 2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = -4.9, -4.8 (SiCH3), 13.7 (CH2I), 18.1 (SiC(CH3)3), 18.2
(cyclopropane CH2), 21.7 (cyclopropane C-2′), 23.5 (cyclopropane C-1′), 25.9 (SiC(CH3)
3), 41.4 (C1′′), 42.8 (C3′′). 55.3 (CH3), 73.6 (CHOR), 113.5, 130.7, 131.3, 158.0 (aromatic
C).
IR (neat): ν~  = 2960, 2928, 2856, 1512, 1257 cm-1.
(3R,5R)-5-[tert-Butyl(dimethyl)silyl]oxy-6-(4-methoxyphenyl)-3-methylhex-1-ene 
(134)
A solution of the crude iodide 133 (230 mg, 0.5 mmol) in dry Et2O (5 mL)
containing 4 Å molecular sieves (88 mg) and TMEDA (150 µL, 1 mmol) was treated with
n-BuLi (2.5 M in hexane, 0.4 mL, 1 mmol) at -78 °C. The resulting mixture was stirred at
-78 °C for 0.5 h, then the temperature was raised to –30 °C over 2 h. The reaction was
quenched with H2O (2 mL). The layers were separated and the aqueous layer was extracted
with Et2O (3 x 5 mL). The combined organic layers were successively washed with 10%
HCl (2 mL), saturated NaHCO3 solution (2 mL), H2O and brine, respectively. The organic
layer was dried (MgSO4), filtered, and concentrated. The crude product was purified by
flash chromatography (petroleum ether/ethyl acetate, 40:1) to give the alkene 134 as a
colorless oil (83 mg, 50% yield, > 97% de). TLC (petroleum ether/ethyl acetate, 40:1): Rf =
0.42; [α]D26 +1.77 (c 0.98, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = -0.19 -0.19, -0.04 (2 s, 3H each, SiCH3), 0.86 (s, 9H, SiC
(CH3)3), 0.97 (d, J = 6.8 Hz, 3H, CHCH3), 1.35-1.42 (m, 1H, H-4), 1.44-1.51 (m, 1H, H-4),
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2.27-2.34 (m, 1H, H-3), 2.58-2.63 (m, 1H, H-6), 2.73-2.78 (m, 1H, H-6), 3.78 (s, 3H,
OCH3), 3.80-3.86 (m, 1H, H-5), 4.95 (d, J = 10.4 Hz, 1H, H-1), 5.00 (d, J = 17.2 Hz, 1H,
H-1), 5.65-5.74 (m, 1H, H-2), 6.82 (d, J = 8.6 Hz, 2H, aromatic H), 7.10 (d, J = 8.3 Hz,
2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = -4.8, -4.7 (SiCH3), 18.0 (SiC(CH3)3), 20.4 (CHCH3),
25.9 (SiC(CH3)3), 34.5 (C-3), 42.7 (C-6), 44.0 (C-4), 55.2 (OCH3), 71.9 (C-5), 112.6 (C-1),
113.5, 130.7, 131.4 (aromatic C), 144.6 (C-2), 157.9 (aromatic C).
IR (neat): ν~  = 3075, 2955, 2929, 2857, 1513, 1248 cm-1.
HRMS: calcd. for C20H34O2SiNa 357.22203, found 357.22193.
(2R,4R)-1-(4-Methoxyphenyl)-4-methylhex-5-en-2-ol (135)
To a stirred solution of the silyl ether 134 (135 mg, 0.4 mmol) in dry THF (3 mL)
at 0 °C was added TBAF (1.0 M in THF, 0.8 mL, 0.8 mmol). The reaction mixture was
allowed to reach room temperature and stirred for 14 h. The reaction was quenched with
saturated NH4Cl solution (2 mL) and the aqueous layer extracted with Et2O (3 x 5 mL).
The combined organic layers were washed with brine (15 mL), dried (MgSO4), filtered,
and concentrated. The crude product was purified by short flash chromatography
(petroleum ether/ethyl acetate 2:1) to yield the alcohol 135 as a colorless oil (53 mg, 60%
yield). TLC (petroleum ether/ethyl acetate, 1:1): Rf = 0.48.   
1H NMR (400 MHz, CDCl3): δ = 1.0 (d, J = 6.8 Hz, 3H, CHCH3), 1.39-1.46 (m, 1H, H-4),
1.52-1.59 (m, 1H, H-4), 1.82 (s, br, 1H, OH), 2.33-2.40 (m, 1H, H-3), 2.54-2.59 (m, 1H, H-
6), 2.74-2.78 (m, 1H, H-6), 3.78 (s, 3H, OCH3), 3.81-3.87 (m, 1H, H-5), 4.94 (d, J = 10.4
Hz, 1H, H-1), 5.03 (d, J = 17.4 Hz, 1H, H-1), 5.72-5.81 (m, 1H, H-2), 6.84 (d, J = 8.6 Hz,
2H, aromatic H), 7.11 (d, J = 8.3 Hz, 2H, aromatic H).
13C NMR (100 MHz, CDCl3): δ = 20.0 (CHCH3), 35.1 (C-3), 43.0 (C-6), 43.4 (C-4), 55.2
(OCH3), 71.1 (C-5), 112.7 (C-1), 113.9, 130.3, 132.4 (aromatic C), 144.9 (C-2), 158.2
(aromatic C).
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(3R,5R)-5-[tert-Butyl(diphenyl)silyl]oxy-6-(4-methoxyphenyl)-3-methylhex-1-ene (139)
To a stirred solution of alcohol 138 (51 mg, 0.24 mmol) in CH2Cl2 (1 mL) was
added imidazole (35 mg, 0.48 mmol) at 0 °C and the mixture stirred for 5 min resulting in
a homogeneous solution. Subsequently, tert-butyldiphenylsilyl chloride (68 µL, 0.26
mmol) was added and the whole mixture stirred for 0.5 h at 0 °C and then at room
temperature for 14 h. The reaction mixture was diluted with H2O, the layers were separated
and the aqueous layer extracted with CH2Cl2 (2 x 3 mL). The combined organic layers
were washed with brine, dried (MgSO4), filtered, and concentrated. The crude product was
purified by flash chromatography (petroleum ether/ethyl acetate 5:1) to yield the silyl ether
139 as a colorless oil (106 mg, 100% yield). TLC (petroleum ether/ethyl acetate, 8:1): Rf =
0.55; [α]D25 +13.4 (c 0.95, CH2Cl2).    
1H NMR (400 MHz, CDCl3): δ = 0.71 (d, J = 6.6 Hz, 3H, CHCH3), 1.04 (s, 9H, SiC(CH3)
3), 1.24-1.31 (m, 1H, H-4), 1.35-1.42 (m, 1H, H-4), 2.20-2.28 (m, 1H, H-3), 2.65-2.76 (m,
2H, H-6), 3.78 (s, 3H, OCH3), 3.86-3.92 (m, 1H, H-5), 4.78 (d, J = 10.1 Hz, 1H, H-1), 4.83
(d, J = 17.2 Hz, 1H, H-1), 5.29-5.38 (m, 1H, H-2), 6.76 (d, J = 8.6 Hz, 2H, aromatic H),
6.89 (d, J = 8.6 Hz, 2H, aromatic H), 7.33-7.46 (m, 6H, aromatic H), 7.59, 7.72 (d, J = 6.6
Hz, 2H each, aromatic H).
13C NMR (100 MHz, CDCl3): δ = 19.3 (SiC(CH3)3), 20.0 (CHCH3), 27.0 (SiC(CH3)3),
34.3 (C-3), 42.6 (C-6), 42.7 (C-4), 55.2 (OCH3), 72.8 (C-5), 112.2 (C-1), 113.5, 127.4,
127.5, 129.4, 129.5, 130.5, 131.0, 134.3, 134.4, 136.0, 136.0 (aromatic C), 144.6 (C-2),
157.9 (aromatic C).
IR (neat): ν~  = 2931, 1508, 1462, 1246, 1084, 1038 cm-1.
HRMS: calcd. for C30H38O2SiNa 481.25333, found 481.25174.
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Ethyl (2E,4S)-4-hydroxyhex-2-enoate (149)
A. TADDOLate-titanium complex
A two-neck flask was charged with TADDOL-Np (148) (1.33 g, 2 mmol), titanium
(IV) isopropoxide (0.60 mL, 2 mmol) and toluene (15 mL). The solution was stirred for 4 h
at room temperature. The reaction mixture was concentrated under reduced pressure at
room temperature with vigorous stirring for 3 h to yield TADDOLate-Ti complex as a
yellow amorphous solid. This complex was used as the alkylation catalyst.
B. Ethylation of ethyl (E)-4-oxobutenoate (144)
To a solution of the TADDOLate-Ti complex (from A), titanium(IV) isopropoxide
(3.60 mL, 12 mmol) and ethyl (E)-4-oxobutenoate (144) (1.20 mL, 10 mmol) in toluene
(40 mL) was added a solution of diethylzinc (1.0 M in hexane, 18 mL, 18 mmol) at -25 °C.
The solution was stirred for 16 h at that temperature. After quenching the reaction with
saturated NH4Cl solution (20 mL) at -25 °C, the mixture was allowed to reach room
temperature and then filtered through celite. The layers were separated and the aqueous
layer extracted with Et2O (3 x 30 mL). The combined organic layers were washed with
brine, dried (MgSO4), filtered, and concentrated to give a pale yellow oil. The crude
product was purified by flash chromatography (petroleum ether/ethyl acetate 4:1) to yield
alcohol 149 as a pale yellow oil (1.00 g, 64% yield, 98% ee). TLC (petroleum ether/ethyl
acetate, 2:1): Rf = 0.42; [α]D27 +23.2 (c 1.12, CH2Cl2) {Ref.139 [α]D20 +25.0 (c 1.83,
CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.94 (t, J = 7.5 Hz, 3H, H-6), 1.26 (t, J = 7.2 Hz, 3H,
OCH2CH3), 1.53-1.66 (m, 2H, H-5), 2.05 (s, br, 1H, OH), 4.13-4.24 (m, 1H, H-4), 4.17 (q,
J = 7.2 Hz, 2H, OCH2CH3), 6.00 (dd, J = 15.7, 1.8 Hz, 1H, H-2), 6.91 (dd, J = 15.7, 5.1
Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = 9.4 (C-6), 14.2 (OCH2CH3), 29.5 (C-5), 60.4
(OCH2CH3), 72.3 (C-4), 120.3 (C-2), 149.9 (C-3), 166.6 (C-1).
IR (neat): ν~  = 3437 (br), 2974, 1712, 1277, 1176, 1041 cm-1.
CO2Et
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Ethyl (2E,4S)-4-hydroxypent-2-enoate (154)  
The TADDOLate-Ti complex was prepared from TADDOL-Np (148) (333 mg, 0.5
mmol), titanium(IV) isopropoxide (0.15 mL, 0.5 mmol) and toluene (5 mL) as described
before. To a solution of the TADDOLate-Ti complex, titanium(IV) isopropoxide (1.8 mL,
6 mmol) and ethyl (E)-4-oxobutenoate (144) (0.60 mL, 5.0 mmol) in toluene (20 mL) was
added a solution of diethylzinc (2.0 M in hexane, 4.5 mL, 9.0 mmol) at -25 °C. The
reaction was stirred for 24 h at that temperature. The other workup manipulations were
carried out as described for the synthesis of 149. The crude product was purified by flash
chromatography (petroleum ether/ethyl acetate 4:1) to yield alcohol 154 as a pale yellow
oil (712 mg, 99% yield, >99% ee). TLC (petroleum ether/ethyl acetate, 2:1): Rf = 0.42; [α]
D
26 +24.7 (c 1.04, CH2Cl2) {Ref.141e [α]D22 +24 (c 2.1, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 1.26 (t, J = 7.1 Hz, 3H, OCH2CH3), 1.31 (d, J = 6.8 Hz,
3H, H-5), 2.30 (s, 1H, OH), 4.17 (q, J = 7.1 Hz, 2H, OCH2CH3), 4.42-4.48 (m, 1H, H-4),
6.00 (dd, J = 15.8, 1.6 Hz, 1H, H-2), 6.93 (dd, J = 15.7, 4.8 Hz, 1H, H-3).
13C NMR (100 MHz, CDCl3): δ = 14.2 (OCH2CH3), 22.6 (C-5), 60.5 (OCH2CH3), 67.1
(C-4), 119.5 (C-2), 151.1 (C-3), 166.7 (C-1).
 IR (neat): ν~  = 3436 (br), 2978, 1712, 1277, 1176, 1045 cm-1.
Ethyl (4S)-4-hydroxyhex-2-enoate (156)
Enoate 156 (159 mg, 1.0 mmol), 10 mol% Pd/C (10%, 18 mg), and dry EtOH (2
mL) was stirred for 54 h under 1 atm of hydrogen and then the mixture was filtered. The
crude product was purified with flash chromatography (petroleum ether/ethyl acetate 4:1)
and the filtrate was concentrated in vacua to yield hydroxy ester 156 as a colorless oil (139
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mg, 87% yield). TLC (petroleum ether/ethyl acetate, 4:1): Rf = 0.42; [α]D26 +0.20 (c 1.13,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.90 (t, J = 7.3 Hz, 3H, H-6), 1.20 (t, J = 6.8 Hz, 3H,
OCH2CH3), 1.38-1.49 (m, 2H, H-5), 1.59-1.68 (m, 1H, H-3), 1.78-1.86 (m, 1H, H-3), 2.31-
2.35 (m, 2H, H-2), 4.08 (q, J = 6.9 Hz, 2H, OCH2CH3).
 13C NMR (100 MHz, CDCl3): δ = 10.3 (C-6), 14.6 (OCH2CH3), 31.2 (C-2), 32.1 (C-3),
34.8 (C-5), 60.8 (OCH2CH3), 73.0 (C-4), 174.7 (C-1).
IR (neat): ν~  = 3552 (br), 2985, 1739, 1373, 1246, 1045 cm-1.
(5S)-5-Ethyltetrahydro-2-furanone (158)
A mixture of 4-hydroxy ester 156 (137 mg, 0.86 mmol), concentrated HCl (0.5 mL)
and H2O (0.5 mL) was heated at 95 °C for 8 h. The organic materials were extracted with
Et2O (3 x 5 mL). The combined organic layers were washed with brine, dried (Na2SO4),
filtered and concentrated to give 156 as a pale orange oil (71 mg, 73%). TLC (petroleum
ether/ethyl acetate, 4:1): Rf = 0.48; [α]D26 –30.5 (c 0.97, CH2Cl2) {Ref.17 [α]D24 -35.2 (c
0.94, CHCl3)}.
1H NMR (400 MHz, CDCl3): δ = 0.98 (t, J = 7.5 Hz, 3H, CH3), 1.59-1.89 (m, 3H,
CH2CHO), 2.26-2.34 (m, 3H, CH2CHO), 2.49-2.54 (m, 2H, CH2COO), 4.38-4.45 (m, 1H,
CH(C2H5)).
13C NMR (100 MHz, CDCl3): δ = 9.4 (CH3), 27.4 (CH2CH3), 28.8 (CH2COO), 82.2 (CH
(C2H5)), 177.3 (C-1).
IR (neat): ν~  = 2966, 1461, 1358, 1180 cm-1.   
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7 APPENDIX
1H- and 13C-NMR spectra of compound 59.
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1H- and 13C-NMR spectra of compound 60.
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1H- and 13C-NMR spectra of compound 61.
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1H- and 13C-NMR spectra of compound 82.
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1H- and 13C-NMR spectra of compound 83.
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1H- and 13C-NMR spectra of compound 89.
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1H- and 13C-NMR spectra of compound 91.
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1H- and 13C-NMR spectra of compound 94.
100 50 0
Chloroform-d
13
4.
07
12
8.
95
78
.7
8
77
.0
0
68
.2
6
44
.2
1
38
.6
3
28
.5
7
25
.9
1
21
.2
8
20
.8
3
18
.3
8
13
.5
2
-5
.2
8
TBSO
OMs
94
5.0 4.5 4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5 0.0
 5.20  5.15 1.40 1.00
136 APPENDIX
1H- and 13C-NMR spectra of compound 109.
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1H- and 13C-NMR spectra of compound 111.
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1H- and 13C-NMR spectra of compound 112.
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1H- and 13C-NMR spectra of compound 113.
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1H- and 13C-NMR spectra of compound 126.
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1H- and 13C-NMR spectra of compound 128.
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1H- and 13C-NMR spectra of compound 129.
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1H- and 13C-NMR spectra of compound 130.
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1H- and 13C-NMR spectra of compound 133.
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1H- and 13C-NMR spectra of compound 134.
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1H- and 13C-NMR spectra of compound 135.
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1H- and 13C-NMR spectra of compound 139.
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7 6 5 4 3 2 1
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1H- and 13C-NMR spectra of compound 149.
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1H- and 13C-NMR spectra of compound 154.
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1H- and 13C-NMR spectra of compound 156.
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1H- and 13C-NMR spectra of compound 158.
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Ethyl (3R)-3-hydroxybutanoate (63)
GC:
Device: HP 5890 Gas Chromatograph, Series II
Column: Chirasil Val (Glas Capillary), 20 m x 0.3 mm
Conditions: Pressure 48 kPa H2
Temperatureprogram: From 60 °C (3 min) 3.5 °C/min to 175 °C
Derivative: Iso-propylurethane
Peak Retention Time Area Area % ee %
1
2
14.81
14.99
13724
246110
5.282
94.718
89
  
GC-Diagram: Derivatives of (a) racemic mixtures. (b) compound 63.
a)
OH
CO2Et
b)
 1
 1
 2
 2
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Ethyl (3S)-3-{[tert-butyl(dimethyl)silyl]oxy}heptanoate (109)
GC:
Device: HP 5890 Gas Chromatograph, Series II
Column: Chirasil Val (Glas Capillary), 20 m x 0.3 mm
Conditions: Pressure 48 kPa H2
Temperatureprogram: From 70 °C (3 min) 3.5 °C/min to 180 °C
Derivative: Iso-propylurethane
Peak Retention Time Area Area % ee %
1a
2a
20.40
20.62
753
18700
3.871
96.129
92
3
4
20.97
21.13
564
15993
3.406
96.594
93
Note: a) The derivatization were not completed.
OTBS
CO2Et
 1
 2
 3
 4
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GC-Diagram: Derivatives of (a) racemic mixtures. (b) compound 109.
 1  2
 4 3
b.1)
b.2)
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(S)-Epichlorohydrin ((S)-121)
GC:
Device: HP 5890 Gas Chromatograph, Series II
Column: Chirasil-Nickel, 20 m x 0.25 mm
Conditions: Pressure 50 kPa H2
Temperatureprogram: From 50 °C (3 min) 4 °C/min to 65 °C for (±)-121
50 °C isoterm for (S)-121
Compound Peak Retention Time Area Area % ee %
(±)-121 1
2
4.892
5.458
42678
42732
49.968
50.032
-
(S)-121 1
2
 2.914
-
1171119
-
100.000
-
> 99
GC-Diagram: (a) racemic mixtures. (b) compound (S)-121.
a)
b)
O
Cl
 1
 1
 2
 2
156 APPENDIX
(2S)-2-(4-methoxybenzyl)oxirane ((S)-123)
GC:
Device: HP 5890 Gas Chromatograph, Series II
Column: Chirasil β-Dex (Fused Silica), 20 m x 0.25 mm
Conditions: Pressure 35 kPa H2
Temperatureprogram: From 70 °C (5 min) 3 °C/min to 140 °C
Peak Retention Time Area Area % ee %
1
2
28.882
29.483
48114
71410
 40.255
59.745
19
GC-Diagram: (a) racemic mixtures. (b) compound 123.
 2
O
MeO
 1
a)
b)
 2
 1
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Ethyl (2E,4S)-4-hydroxyhex-2-enoate (149)
GC:
Device: HP 5890 Gas Chromatograph, Series II
Column: Chirasil β-Dex (Fused Silica), 18 m x 0.25 mm
Conditions: Pressure 35 kPa H2
Temperatureprogram: From 60 °C (2 min) 4 °C/min to 160 °C
Derivative: Iso-propylurethane
Peak Retention Time Area Area % ee %
1
2
6.712
6.915
136246
13260275
 1.017
98.983
98
GC-Diagram: Derivatives of (a) racemic mixtures. (b) compound 149.
a)
b)
CO2Et
OH
 2
 1
 2
 1
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Ethyl (2E,4S)-4-hydroxypent-2-enoate (154)
GC/MSD 6890 / 5973:
Device: HP (Agilent) 5871 Gas Chromatograph, Series II
Column: Chirasil Val (Glas Capillary), 20 m x 0.3 mm
Conditions: Pressure 35 kPa H2
Temperatureprogram: From 60 °C (2 min) 4 °C/min to 160 °C
Derivative: Iso-propylurethane
Peak Retention Time Area Area % ee %
1
2
 25.934
26.062
2096
1624031
 0.129
99.871
99
GC/MSD-Diagram: Derivatives of (a) racemic mixtures. (b) compound 15.
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